[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 513
1. Albano F, Mestice A, Pannunzio A, Lanza F, Martino B, Pastore D, Ferrara F, Carluccio P, Nobile F, Castoldi G, Liso V, Specchia G: The biological characteristics of CD34+ CD2+ adult acute promyelocytic leukemia and the CD34 CD2 hypergranular (M3) and microgranular (M3v) phenotypes. Haematologica; 2006 Mar;91(3):311-6
Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The biological characteristics of CD34+ CD2+ adult acute promyelocytic leukemia and the CD34 CD2 hypergranular (M3) and microgranular (M3v) phenotypes.
  • BACKGROUND AND OBJECTIVES: Acute promyelocytic leukemia (APL) is characterized by leukemic cells blocked at the promyelocytic stage of granulocytic differentiation.
  • To date, it is still not clear whether CD34 expression identifies a subset of APL patients with peculiar characteristics.
  • We, therefore, conducted a detailed analysis of CD34 expression at diagnosis in 136 adults with de novo APL.
  • DESIGN AND METHODS: We investigated 136 newly diagnosed APL patients from four Italian Institutions.
  • All 136 cases were tested for CD34 and CD2 expression: 124 (91%) cases were classified as hypergranular (M3) and 12 (9%) as the hyporgranular M3 variant (M3v).
  • The parameters considered were white blood cell (WBC) and platelet counts, hemoglobin levels, percentage of peripheral blood leukemic promyelocytes (PBLP), CD15, CD56 and HLA-DR expression, and the PML/RARalpha isoform, to assess their relationship with CD34 and CD2 expression.
  • Moreover, compared with CD34- APL patients, CD34+ APL patients had a significantly higher percentage of PBLP at presentation, were more frequently female and had a higher proportion of bcr3 expression.
  • Among the 136 APL cases, 24 (17.6%) and 80 (58.8%) were identified as CD34+CD2+ and CD34-CD2-, respectively.
  • INTERPRETATION AND CONCLUSIONS: Our findings suggest that immunophenotypic analysis can distinguish a subset of APL patients with different biological characteristics.
  • [MeSH-major] Antigens, CD2 / genetics. Antigens, CD34 / biosynthesis. Leukemia, Promyelocytic, Acute / genetics. Phenotype
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Genetic Variation / genetics. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2006 Mar;91(3):289C [16531246.001]
  • (PMID = 16531253.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD2; 0 / Antigens, CD34
  •  go-up   go-down


2. Dbaibo GS, Kfoury Y, Darwiche N, Panjarian S, Kozhaya L, Nasr R, Abdallah M, Hermine O, El-Sabban M, de Thé H, Bazarbachi A: Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity. Haematologica; 2007 Jun;92(6):753-62
Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity.
  • BACKGROUND AND OBJECTIVES: Arsenic trioxide (ATO) is an effective treatment for acute promyelocytic leukemia (APL) and potentially for human T-cell leukemia virus type I (HTLV-I) associated adult T-cell leukemia/lymphoma (ATL).
  • We, therefore, investigated the contribution of ceramide to the mechanism of action of ATO in APL and ATL.
  • DESIGN AND METHODS: A human APL-derived cell line (NB4), various ATL-derived lines and an HTLV-I-negative malignant T-cell line were cultured and treated with ATO.
  • RESULTS: Treatment of APL and ATL-derived cells with a clinically achievable concentration of ATO induced accumulation of cytotoxic levels of ceramide.
  • The effects of ATO on ceramide levels in APL cells were more potent than those of all-trans retinoic acid (ATRA).
  • Interestingly, the effects of ATO on de novo ceramide synthesis were similar in APL and ATL-derived cells despite the defective pathway in ATL cells.
  • [MeSH-major] Arsenicals / pharmacology. Ceramides / biosynthesis. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Oxides / pharmacology

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550847.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Ceramides; 0 / Oxides; EC 2.4.1.- / Glucosyltransferases; EC 2.4.1.80 / ceramide glucosyltransferase; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


3. Adès L, Sanz MA, Chevret S, Montesinos P, Chevallier P, Raffoux E, Vellenga E, Guerci A, Pigneux A, Huguet F, Rayon C, Stoppa AM, de la Serna J, Cahn JY, Meyer-Monard S, Pabst T, Thomas X, de Botton S, Parody R, Bergua J, Lamy T, Vekhoff A, Negri S, Ifrah N, Dombret H, Ferrant A, Bron D, Degos L, Fenaux P: Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood; 2008 Feb 1;111(3):1078-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results.
  • All-trans retinoic acid (ATRA) plus anthracycline chemotherapy is the reference treatment of newly diagnosed acute promyelocytic leukemia (APL), whereas the role of cytosine arabinoside (AraC) remains disputed.
  • We performed a joint analysis of patients younger than 65 years included in Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA) LPA 99 trial, where patients received no AraC in addition to ATRA, high cumulative dose idarubicin, and mitoxantrone, and APL 2000 trial, where patients received AraC in addition to ATRA and lower cumulative dose daunorubicin.
  • This suggested that AraC is not required in APL with WBC count less than 10 x 10(9)/L, at least in trials with high-dose anthracycline and maintenance treatment.
  • In patients with WBC of 10 x 10(9)/L or more, however, the CR rate (95.1% vs 83.6% P = .018) and 3-year survival (91.5% vs 80.8%, P = .026) were significantly higher in APL 2000 trial, and there was a trend for lower 3-year CIR (9.9% vs 18.5%, P = .12), suggesting a beneficial role for AraC in those patients.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / diagnosis. Leukemia, Promyelocytic, Acute / drug therapy
  • [MeSH-minor] Adult. Clinical Trials as Topic. Female. Humans. Male. Middle Aged. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17975017.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Akagi T, Shih LY, Kato M, Kawamata N, Yamamoto G, Sanada M, Okamoto R, Miller CW, Liang DC, Ogawa S, Koeffler HP: Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations. Blood; 2009 Feb 19;113(8):1741-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations.
  • Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.
  • Here, 47 t(15;17) APL samples were analyzed with high-density single-nucleotide polymorphism microarray (50-K and 250-K SNP-chips) using the new algorithm AsCNAR (allele-specific copy-number analysis using anonymous references).
  • Nineteen samples (40%) showed either one or more genomic abnormalities: 8 samples (17%) had trisomy 8 either with or without an additional duplication, deletion, or CNN-LOH (+8 group); and 11 samples (23%) had genomic abnormalities without trisomy 8 (other abnormalities group).
  • Taken together, these results suggest that the pathway of development of APL differs in each group: FLT3-ITD, trisomy 8, and other genomic changes.
  • Here, we showed for the first time hidden abnormalities and novel disease-related genomic changes in t(15;17) APL.

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8283-8 [12060771.001]
  • [Cites] Haematologica. 2009 Feb;94(2):213-23 [19144660.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3188-97 [12515727.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1206-16 [12973844.001]
  • [Cites] Blood. 1984 Feb;63(2):254-9 [6362749.001]
  • [Cites] Nature. 1990 Oct 11;347(6293):558-61 [2170850.001]
  • [Cites] Blood. 1991 Mar 1;77(5):1080-6 [1995093.001]
  • [Cites] Cell. 1991 Aug 23;66(4):675-84 [1652369.001]
  • [Cites] Haematologica. 2000 Jan;85(1):31-4 [10629588.001]
  • [Cites] Blood. 2002 Jan 1;99(1):310-8 [11756186.001]
  • [Cites] Br J Haematol. 2002 Mar;116(4):744-57 [11886377.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2985-91 [11929790.001]
  • [Cites] N Engl J Med. 1993 Jul 15;329(3):177-89 [8515790.001]
  • [Cites] Blood. 1997 Jan 15;89(2):376-87 [9002938.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2551-6 [9122233.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):815-8 [9486655.001]
  • [Cites] Blood. 1999 May 15;93(10):3167-215 [10233871.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):375-8 [15695375.001]
  • [Cites] Blood. 2005 May 1;105(9):3699-706 [15650056.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4792-9 [15718420.001]
  • [Cites] Oncogene. 2005 Jun 9;24(25):4129-37 [15806161.001]
  • [Cites] Blood. 2005 Jul 1;106(1):265-73 [15769897.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6071-9 [16024607.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1153-60 [15889156.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2113-9 [15951308.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Nov;44(3):334-7 [16015648.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9152-4 [16230371.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9234-42 [16275934.001]
  • [Cites] Oncogene. 2006 Mar 13;25(11):1594-601 [16550159.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1708-15 [16675706.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1202-10 [17053054.001]
  • [Cites] Br J Haematol. 2007 Apr;137(1):64-75 [17359372.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Am J Hum Genet. 2007 Jul;81(1):114-26 [17564968.001]
  • [Cites] Br J Haematol. 2007 Sep;138(5):603-15 [17686054.001]
  • [Cites] Blood. 2008 Jan 15;111(2):776-84 [17890455.001]
  • [Cites] Cancer. 2008 Mar 15;112(6):1296-305 [18246537.001]
  • [Cites] Blood. 2008 Aug 1;112(3):814-21 [18490517.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Sep;47(9):729-39 [18506749.001]
  • [Cites] Leuk Lymphoma. 2008 Jun;49(6):1178-83 [18452069.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Nov;35(3):261-70 [12353268.001]
  • (PMID = 19109227.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA026038; United States / NCI NIH HHS / CA / 5R01CA026038-30
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Other-IDs] NLM/ PMC2647673
  •  go-up   go-down


5. Adès L, Guerci A, Raffoux E, Sanz M, Chevallier P, Lapusan S, Recher C, Thomas X, Rayon C, Castaigne S, Tournilhac O, de Botton S, Ifrah N, Cahn JY, Solary E, Gardin C, Fegeux N, Bordessoule D, Ferrant A, Meyer-Monard S, Vey N, Dombret H, Degos L, Chevret S, Fenaux P, European APL Group: Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood; 2010 Mar 4;115(9):1690-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience.
  • Acute promyelocytic leukemia (APL) is highly curable with the combination of all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy (CT), but very long-term results of this treatment, when CT should be added to ATRA and the role of maintenance treatment, remain uncertain.
  • In our APL93 trial that included 576 newly diagnosed APL patients, with a median follow-up of 10 years, 10-year survival was 77%.
  • The 10-year cumulative incidence of deaths in complete response (CR), resulting mainly from myelosuppression, was 5.7%, 15.4%, and 21.7% in patients younger than 55, 55 to 65, and older than 65 years, respectively, supporting the need for less myelosuppressive treatments, particularly for consolidation therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / administration & dosage
  • [MeSH-minor] Adult. Aged. Cytarabine / administration & dosage. Cytarabine / adverse effects. Disease-Free Survival. Europe. Female. Follow-Up Studies. Humans. Male. Middle Aged. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20018913.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00599937
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin
  •  go-up   go-down


6. Tallman MS, Kim HT, Montesinos P, Appelbaum FR, de la Serna J, Bennett JM, Deben G, Bloomfield CD, Gonzalez J, Feusner JH, Gonzalez M, Gallagher R, Miguel JD, Larson RA, Milone G, Paietta E, Rayon C, Rowe JM, Rivas C, Schiffer CA, Vellenga E, Shepherd L, Slack JL, Wiernik PH, Willman CL, Sanz MA: Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. Blood; 2010 Dec 16;116(25):5650-9
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group.
  • Few studies have examined the outcome of large numbers of patients with the microgranular variant (M3V) of acute promyelocytic leukemia (APL) in the all-trans retinoic acid era.
  • The complete remission rate for all 155 patients was 82%, compared with 89% for 748 patients with classical M3 disease.
  • The incidence of the APL differentiation syndrome was 26%, compared with 25% for classical M3 patients, and the early death rate was 13.6% compared with 8.4% for patients with classical M3 morphology.
  • With a median follow-up time among survivors of 7.6 years (range 0.6-14.3), the 5-year overall survival, disease-free survival, and cumulative incidence of relapse among patients with classical M3 morphology were 80% (P = .006 compared with M3V), 81% (P = .07), and 15% (P = .005), respectively.
  • When outcomes were adjusted for the white blood cell count or the relapse risk score, none of these outcomes were significantly different between patients with M3V and classical M3 APL.

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Aug 15;96(4):1247-53 [10942364.001]
  • [Cites] Blood. 2000 Jan 1;95(1):90-5 [10607690.001]
  • [Cites] Leukemia. 2002 Nov;16(11):2185-9 [12399960.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4298-302 [12393590.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3188-97 [12515727.001]
  • [Cites] Br J Haematol. 2003 Aug;122(4):563-70 [12899711.001]
  • [Cites] Best Pract Res Clin Haematol. 2003 Sep;16(3):349-55 [12935955.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1237-43 [14576047.001]
  • [Cites] Cytometry B Clin Cytom. 2004 May;59(1):1-9 [15108165.001]
  • [Cites] Br J Haematol. 2004 May;125(4):463-9 [15142116.001]
  • [Cites] Blood. 1980 Feb;55(2):253-9 [6928105.001]
  • [Cites] Br J Haematol. 1980 Jan;44(1):169-70 [6929699.001]
  • [Cites] Br J Haematol. 1982 Feb;50(2):201-14 [6949609.001]
  • [Cites] Cancer. 1988 Jan 1;61(1):7-13 [3422032.001]
  • [Cites] Am J Hematol. 1989 Apr;30(4):221-7 [2539013.001]
  • [Cites] Blood. 1989 Apr;73(5):1116-22 [2930837.001]
  • [Cites] Blood. 1992 Aug 1;80(3):582-6 [1353379.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1413-8 [1517784.001]
  • [Cites] Blood. 1993 Mar 15;81(6):1666 [8095829.001]
  • [Cites] Blood. 1993 Jun 1;81(11):3083-90 [8499643.001]
  • [Cites] Leukemia. 1995 Feb;9(2):238-43 [7869758.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1717-28 [7655004.001]
  • [Cites] Leukemia. 1995 Sep;9(9):1461-6 [7658712.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1014-21 [9242531.001]
  • [Cites] Blood. 1997 Aug 15;90(4):1656-63 [9269786.001]
  • [Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]
  • [Cites] Am J Hematol. 1997 Nov;56(3):131-42 [9371524.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1035-41 [9734655.001]
  • [Cites] Br J Haematol. 1998 Dec;103(3):729-39 [9858224.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1192-200 [10438706.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Jun;43(2):113-27 [15751046.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1153-60 [15889156.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3768-76 [16105978.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3395-402 [18195095.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3130-4 [18664623.001]
  • [Cites] Ann Oncol. 2008 Nov;19(11):1927-34 [18567608.001]
  • [Cites] Blood. 2009 Jan 22;113(4):775-83 [18945964.001]
  • [Cites] Haematologica. 2010 May;95(5):745-51 [20133893.001]
  • [Cites] Blood. 1999 Nov 1;94(9):3015-21 [10556184.001]
  • [Cites] Am J Hematol. 2001 May;67(1):34-41 [11279655.001]
  • (PMID = 20858857.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA12213; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / CA31936; United States / NCI NIH HHS / CA / CA66636; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / U10 CA017145; United States / NCI NIH HHS / CA / U10 CA014028; United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / U10 CA066636; United States / NCI NIH HHS / CA / R01 CA056771; United States / NCI NIH HHS / CA / CA17145; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / U10 CA023318; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / U24 CA114737; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA56771
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin; ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ PMC3031411
  •  go-up   go-down


7. Helwig A, Klemm M, Schüttig R, Röllig C, Wassilew N, Ehninger G, Illmer T: Arsenic-induced APL differentiation in cerebrospinal fluid. Leuk Res; 2007 May;31(5):703-5
Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arsenic-induced APL differentiation in cerebrospinal fluid.
  • Although new approaches have dramatically improved, the treatment of acute promyelocytic leukemia (APL) involvement of the central nervous system (CNS) confers a bad prognosis in the disease.
  • Here, we report a patient who was diagnosed with relapsed APL preferentially involving the CNS.
  • Since arsenic trioxide could be identified in the CNS, we provide evidence that the drug can cross the blood-brain barrier and can be used for treatment of extramedullary APL.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Brain Neoplasms / drug therapy. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use
  • [MeSH-minor] Adult. Cell Differentiation. Cerebrospinal Fluid / cytology. Female. Humans. Leukocytes / pathology. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16876245.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


8. Shen HQ, Tang YM, Song H, Shi SW, Yang SL, Xu WQ, Qian BQ: [Expressions of CD117 and CD11b in patients with APL at diagnosis and post-treatment]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug;14(4):644-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of CD117 and CD11b in patients with APL at diagnosis and post-treatment].
  • The aim of this study was to evaluate the value of CD117/CD11b phenotypic analysis to diagnosis and prognosis of acute promyelocytic leukemia (APL).
  • Three- or four-color flow cytometry with a series of 22 monoclonal antibodies and CD45/Side Scatter (SSC) gating strategy were used to identify immunophenotypic characteristics of APL as compared to CML in chronic phase (CML-CP).
  • PML/RAR alpha fusion gene was detected by using reverse-transcription polymerase chain reaction (RT-PCR) technique.
  • The results showed that MPO, CD13 and CD33 were almost expressed in all patients with APL and CML-CP whereas HLA-DR and CD34, the hematopoietic progenitor cell markers, were rarely expressed.
  • The positive rate of CD15 in APL was significantly lower than those in CML-CP (P < 0.01).
  • CD117 was positive in 78.3% of the APL cases and in none of the cases of CML-CP.
  • On the other hand, CD11b was almost positive in all cases of CML-CP, but only 16.9% of the APL cases were found positive for this antigen.
  • The CD117+ CD11b- phenotype was present in 72.3% of APL cases while none of cases with CML-CP with this phenotype.
  • CD117- CD11b+ phenotype was detected in all patients recovering from APL with CD117+ CD11b- phenotype at diagnosis and after treatment with all-trans-retinoic acid (ARTA) for 2 months.
  • PML/RAR alpha fusion gene was positive in 80.6% (25/31) of the APL cases, of which, 64% of the cases belonged to the type L while only 36% of the cases were showed type S for this fusion gene.
  • It is concluded that analysis of both CD117 and CD11b phenotype may be helpful to the diagnosis, therapy and prognosis of APL in children and adults and to differentiation of APL from recovering benign myeloid proliferation.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16928291.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD11b; 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


9. Gupta V, Yi QL, Brandwein J, Lipton JH, Messner HA, Schuh AC, Wells RA, Minden MD: Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL). Leuk Res; 2005 Jan;29(1):113-4
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL).
  • The role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL) is undefined at present.
  • Between 1994 and 1999, we treated 38 newly diagnosed APL patients with ATRA and chemotherapy during the induction and consolidation.
  • The role of ATRA during consolidation therapy of APL merits further investigation as this may allow shortening the overall duration of APL treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Remission Induction. Survival Rate

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15541484.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 5688UTC01R / Tretinoin
  •  go-up   go-down


10. Jeddi R, Hdiji S, Kacem K, Ben Lakhal R, Aissaoui L, Ben Abid H, Belhadj Ali Z, Meddeb B: [Therapeutic results with apl 93 protocol in acute promyelocytic leukemia (34 cases)]. Tunis Med; 2006 Nov;84(11):717-20
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic results with apl 93 protocol in acute promyelocytic leukemia (34 cases)].
  • BACKGROUND: Acute promyelocytic leukaemia (APL) account for approximately 10% to 15% of all AML in most reports.
  • Clinical features includes the presence in 80% to 90% of patients of a severe hemorrhagic syndrome, a specific balanced translocation between chromosomes 15 and 17 with a fusion of a large pert of the retinoic acid receptor a gene (RARa) on chromosome 17 to a part of the promyelocytic leukaemia (PML) gene on chromosome 15.
  • AIM: of the study was to assess of the therapeutic management of APL 93 protocol in acute promyelocytic leukemia.
  • METHODS: We present here the results of a retrospective study concerning 34 patients with APL included between 1998 and 2004 in the APL 93 protocol : 20 in group B and 14 in group C.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Anthracyclines / administration & dosage. Child. Chromosomes, Human, Pair 15 / genetics. Chromosomes, Human, Pair 17 / genetics. Female. Humans. Male. Middle Aged. Pilot Projects. Receptors, Retinoic Acid. Remission Induction. Retrospective Studies. Survival Analysis. Translocation, Genetic. Tretinoin / administration & dosage. Tunisia

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17294898.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Tunisia
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor alpha; 5688UTC01R / Tretinoin
  •  go-up   go-down


11. Chen Y, Gu L, Zhou C, Wu X, Gao J, Li Q, Zhu Y, Jia C, Ma Z: Relapsed APL patient with variant NPM-RARalpha fusion responded to arsenic trioxide-based therapy and achieved long-term survival. Int J Hematol; 2010 May;91(4):708-10
Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapsed APL patient with variant NPM-RARalpha fusion responded to arsenic trioxide-based therapy and achieved long-term survival.
  • The t(5;17)/NPM-RARalpha is the second variant chromosomal translocation in acute promyelocytic leukemia (APL) to be characterized and also the second most plentiful variant translocation.
  • So far, there is a lack of information on the effectiveness of arsenic trioxide (ATO) in relapsed APL with variant RARalpha chimera including t(5;17)/NPM-RARalpha.
  • We report here a long-term survived APL patient with variant NPM-RARalpha fusion who relapsed four times and each time responded well to ATO or ATO-based re-induction therapy.
  • This case illustrates the long-term efficiency and safety of ATO-based therapy not only in newly diagnosed APL, but also in relapsed APL including those with variant translocations.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / genetics. Oncogene Proteins, Fusion / genetics. Oxides / therapeutic use
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Recurrence. Remission Induction

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2007 Dec 1;110(12 ):4073-6 [17712046.001]
  • [Cites] Oncogene. 1999 Jan 28;18(4):1113-8 [10023688.001]
  • [Cites] Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008 Aug;25(4):430-3 [18683144.001]
  • [Cites] Blood. 2009 Feb 26;113(9):1875-91 [18812465.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3852-60 [11559723.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2505-15 [18299451.001]
  • [Cites] Best Pract Res Clin Haematol. 2003 Sep;16(3):387-408 [12935958.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2627-32 [16352810.001]
  • [Cites] Leukemia. 2002 Oct;16(10):1927-32 [12357344.001]
  • [Cites] Int J Hematol. 2007 Oct;86(3):246-9 [17988991.001]
  • [Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3342-7 [19225113.001]
  • [Cites] Am J Hematol. 2002 Aug;70(4):292-9 [12210810.001]
  • (PMID = 20405253.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / NPM-RARalpha protein, human; 0 / Oncogene Proteins, Fusion; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


12. Kelaidi C, Chevret S, De Botton S, Raffoux E, Guerci A, Thomas X, Pigneux A, Lamy T, Rigal-Huguet F, Meyer-Monard S, Chevallier P, Maloisel F, Deconinck E, Ferrant A, Fegueux N, Ifrah N, Sanz M, Dombret H, Fenaux P, Adès L: Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol; 2009 Jun 1;27(16):2668-76
Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience.
  • PURPOSE: Acute promyelocytic leukemia (APL) with pretreatment WBC counts greater than 10,000/microL is still considered to carry a poorer prognosis than APL with WBC lower than 10,000/mL.
  • PATIENTS AND METHODS: Nine hundred two patients with APL, including 204 patients and 68 patients with WBC counts more than 10,000/microL and more than 50,000/microL, respectively, were enrolled between 1993 and 2005 in two successive randomized trials of the European APL group (APL 93 and APL 2000) that tested, in particular, the modalities of combination of all-trans retinoic acid (ATRA) and chemotherapy, maintenance treatment, escalating doses of cytarabine, early administration of dexamethasone, and CNS prophylaxis.
  • RESULTS: Between the APL 93 and 2000 trials, the complete response (CR) rate increased from 89.6% to 93%, and the 5-year cumulative incidence of relapse (CIR) decreased from 40% to 9.5% in patients with WBC counts of 10,000 to 50,000/microL.
  • Whereas in the APL 93 trial, increased WBC counts were significantly associated with higher CIR and shorter survival, this was not the case in the APL 2000 trial.
  • In patients with increased WBC counts, enrollment onto the APL 2000 trial (v APL 93) and combined maintenance with ATRA and chemotherapy were associated with significantly lower CIR and better survival.
  • CONCLUSION: Outcome of APL with high WBC count has markedly improved over the years as a result of fewer early deaths and fewer relapses.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Leukocyte Count. Outcome and Process Assessment (Health Care). Quality of Health Care
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Disease-Free Survival. Europe. Female. Humans. Infant. Kaplan-Meier Estimate. Male. Middle Aged. Proportional Hazards Models. Recurrence. Risk Assessment. Risk Factors. Time Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 Jan 10;28(2):e21; author reply e22-3 [19949004.001]
  • (PMID = 19414681.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Li Y, Chen S, Yang L, Zhou Y, Wu X, Huang M, Geng S: Clonal expanded TCR Vbeta T cells in patients with APL. Hematology; 2005 Apr;10(2):135-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal expanded TCR Vbeta T cells in patients with APL.
  • T-cell receptor Vss gene repertoire and clonality have been studied in patients with leukemia and solid tumors, by assaying the CDR3 size of TCR genes, using RT-PCR and genescan analysis.
  • Few studies have studied leukemia-associated oligoclonal expanded T-cells in leukemia, therefore, the aim of this study was to investigate the distribution and clonal expansion of T-cell receptor, Vss subfamily T-cells in patients with acute promyelocytic leukemia (APL) with t(15;17).
  • The CDR3 of TCR Vbeta24 subfamily genes were analyzed in peripheral blood mononuclear cells from 17 cases with PML-RARalpha+ APL using RT-PCR and genescan technique.
  • The results showed that the number of expressed Vss subfamilies (from 2 to 21 subfamilies) varied in different patients with APL.
  • Clonally expanded T-cells in the Vss subfamilies could be identified in patients with APL in all but two of the cases studied, predominantly in Vbeta10, Vbeta23, Vbeta3 and Vbeta21.
  • In conclusion, skewed distribution and clonal expansion of TCR Vss subfamily T-cells could be found in patients with APL.
  • The clonal expansion of T-cells were considered to be a specific anti-leukemic immune response by host T-cells activated by the leukemia-associated-antigen.
  • [MeSH-major] Gene Expression Regulation, Leukemic / genetics. Gene Rearrangement, T-Lymphocyte / genetics. Genes, T-Cell Receptor beta / genetics. Leukemia, Promyelocytic, Acute / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Chromosomes, Human, Pair 15 / genetics. Chromosomes, Human, Pair 15 / immunology. Chromosomes, Human, Pair 17 / genetics. Chromosomes, Human, Pair 17 / immunology. Female. Humans. Male. Middle Aged. Translocation, Genetic / genetics. Translocation, Genetic / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019459.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


14. Callens C, Chevret S, Cayuela JM, Cassinat B, Raffoux E, de Botton S, Thomas X, Guerci A, Fegueux N, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Ferrand A, Sanz M, Chomienne C, Fenaux P, Dombret H, European APL Group: Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia; 2005 Jul;19(7):1153-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.
  • Internal tandem duplications (ITDs) of the FLT3 gene have been observed in about 35% of APL cases.
  • If FLT3-ITD is associated with a worse outcome in patients with acute myeloid leukemia (AML) in general, its prognostic value in acute promyelocytic leukemia (APL) is still a matter of debate.
  • We investigated incidence, associated clinical features, and prognostic implication of FLT3-ITD, but also FLT3-D835 point mutation and N-Ras or K-Ras mutations in 119 APL patients, all prospectively enrolled in the two consecutive APL-93 and APL-2000 trials.
  • The presence of FLT3-ITD was associated with high white blood cell count, high Sanz index, M3-variant subtype, and V/S PML-RAR alpha isoforms.
  • [MeSH-major] Genes, ras / genetics. Leukemia, Promyelocytic, Acute / genetics. Proto-Oncogene Proteins / genetics. Receptor Protein-Tyrosine Kinases / genetics
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic / statistics & numerical data. Europe. Female. Gene Duplication. Humans. Male. Middle Aged. Mutation. Predictive Value of Tests. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome. fms-Like Tyrosine Kinase 3

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15889156.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


15. Pemmaraju N, Kantarjian H, Ravandi F, O'Brien S, Wierda W, Thomas D, Garcia-Manero G, Borthakur G, Pierce S, Cortes J: Acute myeloid leukemia (AML) in adolescents and young adults (AYA): The M. D. Anderson Cancer Center (MDACC) experience. J Clin Oncol; 2009 May 20;27(15_suppl):7051

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia (AML) in adolescents and young adults (AYA): The M. D. Anderson Cancer Center (MDACC) experience.
  • RESULTS: Among 3,934 adult AML pts treated during this period, 163 pts (4%) were AYA with median age of 19 yrs.
  • This cohort included 27 (17%) pts with Core Binding Factor (CBF)-AML [inv(16), t(8:21)] and 19 pts (12%) with acute promyelocytic leukemia (APL).
  • Complete remission (CR) rates were 89% for CBF AML, 79% for APL, and 75% for all other pts.
  • Outcome is better for pts with CBF leukemia (3 yr survival 56%, sustained CR 49%) and APL (3 yr survival 51%, sustained CR 36%) compared to other AML (3 yr survival 28%, sustained CR 24%).
  • Despite the advances in treatments over time, there is still significant room for improvement, particularly among those AYA with AML other than CBF and APL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961415.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Pendino F, Hillion J, Dudognon C, Delaunay J, Mourah S, Podgorniak MP, Lafon I, Chomienne C, Lanotte M, Dombret H, Rousselot P, Ségal-Bendirdjian E: Telomerase targeting by retinoids in cells from patients with myeloid leukemias of various subtypes, not only APL. Leukemia; 2006 Apr;20(4):599-603

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomerase targeting by retinoids in cells from patients with myeloid leukemias of various subtypes, not only APL.
  • Recently, we have shown that long-term treatment with all-trans retinoic acid (ATRA), a compound clinically approved for differentiation therapy of acute promyelocytic leukemia (APL), represses hTERT in differentiation-resistant APL cell lines leading to telomere shortening and death.
  • In contrast to differentiation-therapy, which is only successful in this subtype of leukemia, the telomerase-targeted pathway could also be of use in non-APL.
  • [MeSH-major] Antineoplastic Agents / pharmacology. DNA-Binding Proteins / antagonists & inhibitors. Leukemia, Myeloid / drug therapy. Leukemia, Promyelocytic, Acute / drug therapy. Retinoids / pharmacology. Telomerase / antagonists & inhibitors
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Death / drug effects. Cell Differentiation / drug effects. Cell Line, Tumor. Female. Gene Expression Regulation, Enzymologic / drug effects. Gene Expression Regulation, Leukemic / drug effects. Humans. Male. Middle Aged. RNA, Messenger / drug effects. RNA, Messenger / genetics. Structure-Activity Relationship. Telomere / drug effects. Telomere / genetics. Treatment Outcome. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16482212.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / Retinoids; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


17. Wang L, Li Y, Wang PP, Lu XL, Wang BX: [Role of P27(Kip1) and TGF-beta1 in APL cell apoptosis induced by As(2)O(3)]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr;17(2):324-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of P27(Kip1) and TGF-beta1 in APL cell apoptosis induced by As(2)O(3)].
  • The aim of study was to investigate the effects of arsenic trioxide (As(2)O(3)) on cell cycle and apoptosis of APL cells, as well as changes of P27(Kip1), endogenous TGF-beta1, cyclin E and bcl-2, and to explore the relationship between expression of P27(Kip1) and apoptosis induced by As(2)O(3).
  • The apoptosis and cell cycle changes of APL cells treated with As(2)O(3) were detected by morphology and flow cytometry respectively, the protein and mRNA expressions of P27(Kip1), TGF-beta1, cyclin E and BCL-2 were measured by immunohistochemistry and RT-PCR.
  • The results indicated that As(2)O(3) induced APL cell apoptosis in vitro, and cell cycle was arrested at G(1) phase.
  • Protein and mRNA expressions of P27(Kip1) and TGF-beta1 of APL cells after treatment with As(2)O(3) increased, accompanying with decrease of cyclin E, bcl-2 protein and mRNA expressions.
  • It is concluded that the apoptosis of APL cells is induced by As(2)O(3), and the cell cycle is arrested at G(1) phase.
  • Apoptosis of APL cells induced by As(2)O(3) may be caused by up-regulating TGF-beta1 and P27(Kip1), which is antagonistic to cyclin E and BLC-2, leading to arrest of cell cycle at G(1) phase.

  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19379560.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Arsenicals; 0 / CDKN1B protein, human; 0 / Oxides; 0 / Transforming Growth Factor beta1; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


18. Wang T, Qiu JY, Yu CF, Ma XL, Jia XP, Wang YP, Liu HX, Lin YH, Tong CR, Lu DP: [Analysis of variant translocation der ins (17; 15) in patient with APL by G-banding technique and interphase fluorescence in situ hybridization]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun;17(3):537-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of variant translocation der ins (17; 15) in patient with APL by G-banding technique and interphase fluorescence in situ hybridization].
  • To investigate the biological characteristics of the variant translocation der ins (17;15) in a patient with acute promyelocytic leukemia (APL), the conventional G-banding technique, interphase fluorescence in situ hybridization (int-FISH), RT-PCR, gene scanning, gene sequence and flow cytometry were performed.
  • The results indicated that the variant translocation der ins (17, 15) observed by G banding technique was a rare type, the int-FISH assay by using dual-color pml/raralpha fusion probes confirmed the cytogenetic findings.
  • The detection results of other molecular methods demonstrated the existence of the whole pml/raralpha fusion gene, while this case had insertion variant translocation.
  • In conclusion, the variant translocation der ins (17;.
  • 15) is rare type in APL, its incidence is lower, several signal types in detection of int-FISH were observed and the combination chemotherapy for this patient showed more obvious efficacy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19549359.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


19. Aljurf M, Al Qurashi F, Al Mohareb F, Sahovic E, Al Sharif F, Al Zahrani H, Al Shanqeeti A, Owaidah T, Iqbal A, Zaidi SZ, Nurgat ZA, Sanz M, Chaudhri N: High efficacy and low toxicity of APL induction with concurrent idarubicin/ATRA followed by a novel and simplified outpatient post-remission therapy using single doses of idarubicin and intermittent ATRA. Med Oncol; 2010 Sep;27(3):702-7
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High efficacy and low toxicity of APL induction with concurrent idarubicin/ATRA followed by a novel and simplified outpatient post-remission therapy using single doses of idarubicin and intermittent ATRA.
  • Acute promyelocytic leukemia (APL) is one of the most curable myeloid malignancies because of its great sensitivity to all-trans retinoic acid (ATRA) and response to anthracycline therapy.
  • In an attempt to simplify post-remission therapy, deliver adequate dose of anthracycline and reduce treatment related toxicity, we entered 26 consecutively newly diagnosed, previously untreated APL patients in a pilot treatment program consisting of concurrent induction using idarubicin/ATRA followed by an exclusive outpatient post-remission therapy using single dose of idarubicin and intermittent ATRA, every 4 weeks.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Ambulatory Care. Clinical Trials as Topic / statistics & numerical data. Dexamethasone / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Factor VIII / therapeutic use. Female. Fibrinogen / analysis. Fibrinogen / therapeutic use. Hemorrhage / chemically induced. Hemorrhage / drug therapy. Humans. Idarubicin / administration & dosage. Idarubicin / adverse effects. Kaplan-Meier Estimate. Male. Middle Aged. Pilot Projects. Remission Induction. Tretinoin / administration & dosage. Tretinoin / adverse effects. Young Adult

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1992 Nov 1;80(9):2176-81 [1421389.001]
  • [Cites] Blood. 1991 Sep 15;78(6):1413-9 [1884013.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1717-28 [7655004.001]
  • [Cites] Blood. 1993 Dec 1;82(11):3241-9 [8241496.001]
  • [Cites] Blood. 1999 Nov 1;94(9):3015-21 [10556184.001]
  • [Cites] Leukemia. 1993 Nov;7(11):1722-7 [8231241.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1237-43 [14576047.001]
  • [Cites] Blood. 2010 Oct 28;116(17):3171-9 [20644121.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3019-25 [15604216.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):483-90 [9053469.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3141-6 [12384411.001]
  • [Cites] Nouv Rev Fr Hematol. 1984;26(6):371-8 [6597407.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1014-21 [9242531.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3330-7 [9363862.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1247-53 [10942364.001]
  • [Cites] Haematologica. 1987 Mar-Apr;72(2):151-5 [3114070.001]
  • [Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]
  • [Cites] Semin Hematol. 2004 Apr;41(2 Suppl 4):27-32 [15190513.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1202-6 [7858250.001]
  • (PMID = 19669610.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / cryoprecipitate coagulum; 5688UTC01R / Tretinoin; 7S5I7G3JQL / Dexamethasone; 9001-27-8 / Factor VIII; 9001-32-5 / Fibrinogen; ZRP63D75JW / Idarubicin
  •  go-up   go-down


20. Sun AN, Zhou HX, Wu DP, Wang W, Jin ZM, Qiu HY: [Clinical significance of PML/RARalpha isoforms in adult patients with acute promyelocytic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun;13(3):500-2
Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of PML/RARalpha isoforms in adult patients with acute promyelocytic leukemia].
  • To evaluate the relation of PML/RARalpha isoforms in adult APL patients to clinical therapy and prognosis, the picture of blood and bone marrow aspirates for 71 APL patients treated by induction therapy were peridically examined and the different transcripts of PML/RARalpha were assayed by nested RT-PCR.
  • In conclusion, PML/RARalpha isoforms in patients with APL may be the independent prognostic factor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15972151.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / Protein Isoforms; 0 / Receptors, Retinoic Acid; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
  •  go-up   go-down


21. Kurkjian C, Patel S, Kamble R, Dunn ST, Kern W, Kharfan-Dabaja MA: Acute promyelocytic leukemia and constitutional trisomy 21. Cancer Genet Cytogenet; 2006 Mar;165(2):176-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute promyelocytic leukemia and constitutional trisomy 21.
  • The incidence of acute myelogenous leukemia (AML) in patients with constitutional trisomy 21 is estimated to be 1 in 300; it is usually seen before age four.
  • Clinical and epidemiological data confirm the improved life expectancy of patients with Down syndrome and their increased susceptibility to the development of leukemia, among other cancers.
  • The most frequent subtype of AML associated with Down syndrome is acute megakaryoblastic leukemia (FAB: M7).
  • The description of acute promyelocytic leukemia (APL) in adult patients with Down syndrome is exceedingly rare.
  • Herein, we describe the unusual presentation, treatment, results, and clinical course of an adult patient with APL and constitutional trisomy 21 and provide a brief review of the literature.
  • [MeSH-major] Down Syndrome. Leukemia, Promyelocytic, Acute / genetics
  • [MeSH-minor] Adult. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527614.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Sazawal S, Hasan SK, Dutta P, Kumar B, Kumar R, Kumar L, Choudhry VP, Saxena R: Over-representation of bcr3 subtype of PML/RARalpha fusion gene in APL in Indian patients. Ann Hematol; 2005 Nov;84(12):781-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Over-representation of bcr3 subtype of PML/RARalpha fusion gene in APL in Indian patients.
  • Thirty six patients with acute promyelocytic leukemia were studied by reverse transcriptase-polymerase chain reaction (RT-PCR) and real-time PCR.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Leukemia, Promyelocytic, Acute / blood. Neoplasm Proteins / biosynthesis. Oncogene Proteins, Fusion / biosynthesis. Proto-Oncogene Proteins c-bcr / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. India. Leukocyte Count. Male. Middle Aged. Prevalence. Protein Isoforms / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16132910.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / Protein Isoforms; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; EC 2.7.11.1 / Proto-Oncogene Proteins c-bcr
  •  go-up   go-down


23. Hada K, Asahina M, Hasegawa H, Kanaho Y, Slack FJ, Niwa R: The nuclear receptor gene nhr-25 plays multiple roles in the Caenorhabditis elegans heterochronic gene network to control the larva-to-adult transition. Dev Biol; 2010 Aug 15;344(2):1100-9
SciCrunch. WormBase: Data: Gene Expression .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The nuclear receptor gene nhr-25 plays multiple roles in the Caenorhabditis elegans heterochronic gene network to control the larva-to-adult transition.
  • Here we report that the nuclear receptor nhr-25, which belongs to the evolutionarily conserved fushi tarazu-factor 1/nuclear receptor NR5A subfamily, interacts with heterochronic genes that regulate the larva-to-adult transition in C. elegans.
  • We identified nhr-25 as a regulator of apl-1, a homolog of the Alzheimer's amyloid precursor protein-like gene that is downstream of let-7 family microRNAs.
  • NHR-25 controls not only apl-1 expression but also regulates developmental progression in the larva-to-adult transition.
  • NHR-25 negatively regulates the expression of the adult-specific collagen gene col-19 in lateral epidermal seam cells.
  • In contrast, NHR-25 positively regulates the larva-to-adult transition for other timed events in seam cells, such as cell fusion, cell division and alae formation.
  • The genetic relationships between nhr-25 and other heterochronic genes are strikingly varied among several adult developmental events.
  • We propose that nhr-25 has multiple roles in both promoting and inhibiting the C. elegans heterochronic gene pathway controlling adult differentiation programs.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] Nature. 2000 Feb 24;403(6772):901-6 [10706289.001]
  • [Cites] Dev Biol. 2008 Mar 15;315(2):418-25 [18262516.001]
  • [Cites] Mol Cell. 2000 Apr;5(4):659-69 [10882102.001]
  • [Cites] Curr Opin Genet Dev. 2000 Aug;10(4):428-33 [10889059.001]
  • [Cites] Genes Cells. 2000 Sep;5(9):711-23 [10971653.001]
  • [Cites] Nature. 2000 Nov 2;408(6808):86-9 [11081512.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):325-30 [11099033.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7360-5 [11416209.001]
  • [Cites] Cell. 2001 Aug 24;106(4):511-21 [11525736.001]
  • [Cites] Dev Cell. 2001 Oct;1(4):453-65 [11703937.001]
  • [Cites] Bioessays. 2002 Feb;24(2):119-29 [11835276.001]
  • [Cites] Nature. 2003 Jan 16;421(6920):231-7 [12529635.001]
  • [Cites] Dev Dyn. 2003 Mar;226(3):523-39 [12619137.001]
  • [Cites] Dev Cell. 2003 May;4(5):625-37 [12737799.001]
  • [Cites] Dev Cell. 2003 May;4(5):639-50 [12737800.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52340-6 [14559923.001]
  • [Cites] Dev Biol. 2004 Feb 15;266(2):399-416 [14738886.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(17):7345-58 [15314147.001]
  • [Cites] Dev Biol. 1977 Mar;56(1):110-56 [838129.001]
  • [Cites] Science. 1984 Oct 26;226(4673):409-16 [6494891.001]
  • [Cites] Development. 1992 Dec;116(4):855-63 [1295739.001]
  • [Cites] Development. 1995 Aug;121(8):2491-500 [7671813.001]
  • [Cites] Development. 1996 Aug;122(8):2517-27 [8756296.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6803-8 [9192646.001]
  • [Cites] Development. 1998 May;125(9):1617-26 [9521900.001]
  • [Cites] Genetics. 1998 Jul;149(3):1335-51 [9649524.001]
  • [Cites] Nature. 1998 Oct 29;395(6705):854 [9804418.001]
  • [Cites] J Cell Sci. 2005 Jan 1;118(Pt 1):223-32 [15615786.001]
  • [Cites] Dev Cell. 2005 Feb;8(2):287-95 [15691769.001]
  • [Cites] Dev Cell. 2005 Mar;8(3):321-30 [15737928.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Development. 2005 Sep;132(17):3787-98 [16100088.001]
  • [Cites] Dev Cell. 2005 Sep;9(3):415-22 [16139229.001]
  • [Cites] Trends Endocrinol Metab. 2008 Jul;19(5):153-60 [18406164.001]
  • [Cites] Development. 2008 Dec;135(23):3859-69 [18948419.001]
  • [Cites] Science. 2009 Apr 3;324(5923):95-8 [19342589.001]
  • [Cites] J Cell Sci. 2009 Sep 1;122(Pt 17):3051-60 [19654209.001]
  • [Cites] Dev Biol. 2009 Oct 15;334(2):523-34 [19627983.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18668-73 [19828440.001]
  • [Cites] Nat Genet. 2009 Jun;41(6):729-33 [19448623.001]
  • [Cites] Dev Cell. 2005 Sep;9(3):403-14 [16139228.001]
  • [Cites] Science. 1999 Nov 5;286(5442):1141-6 [10550049.001]
  • [Cites] PLoS Biol. 2005 Oct;3(10):e312 [16122351.001]
  • [Cites] Dev Dyn. 2005 Dec;234(4):868-77 [16217741.001]
  • [Cites] Dev Biol. 2006 Jan 1;289(1):30-43 [16300753.001]
  • [Cites] Curr Biol. 2006 Mar 7;16(5):460-71 [16458514.001]
  • [Cites] Development. 2006 Jun;133(11):2211-22 [16672334.001]
  • [Cites] Dev Cell. 2006 Aug;11(2):203-11 [16890160.001]
  • [Cites] Development. 2006 Dec;133(23):4631-41 [17065234.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 6;104(6):1971-6 [17267616.001]
  • [Cites] Curr Biol. 2007 Jun 5;17(11):R425-34 [17550772.001]
  • [Cites] Dev Biol. 2000 May 1;221(1):259-72 [10772806.001]
  • (PMID = 20678979.001).
  • [ISSN] 1095-564X
  • [Journal-full-title] Developmental biology
  • [ISO-abbreviation] Dev. Biol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM064701; United States / NIGMS NIH HHS / GM / R01 GM064701-08; United States / NIGMS NIH HHS / GM / GM64701
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Receptors, Cytoplasmic and Nuclear
  • [Other-IDs] NLM/ NIHMS212154; NLM/ PMC2915939
  •  go-up   go-down


24. Nakamura M, Hamasaki T, Tokitou M, Baba M, Hashimoto Y, Aoyama H: Discovery of tetrahydrotetramethylnaphthalene analogs as adult T-cell leukemia cell-selective proliferation inhibitors in a small chemical library constructed based on multi-template hypothesis. Bioorg Med Chem; 2009 Jul 1;17(13):4740-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery of tetrahydrotetramethylnaphthalene analogs as adult T-cell leukemia cell-selective proliferation inhibitors in a small chemical library constructed based on multi-template hypothesis.
  • Adult T cell leukemia (ATL), caused by infection of human T-lymphotropic virus type 1 (HTLV-1), has a poor prognosis and curative therapy is unavailable, so it is important to find or design superior lead compounds for the drug treatment of ATL.
  • We used our micro-reversed fragment-based drug design hypothesis and multi-template hypothesis to extract the tetrahydrotetramethylnaphthalene (TMN) skeleton from tamibarotene, a useful medicament for the treatment of acute promyelocytic leukemia (APL).
  • [MeSH-major] Antineoplastic Agents / chemistry. Antineoplastic Agents / pharmacology. Cell Proliferation / drug effects. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Tetrahydronaphthalenes / chemistry. Tetrahydronaphthalenes / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443225.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Retinoids; 0 / Small Molecule Libraries; 0 / Tetrahydronaphthalenes
  •  go-up   go-down


25. Niwa R, Hada K: Identification of a spatio-temporal enhancer element for the Alzheimer's amyloid precursor protein-like-1 gene in the nematode Caenorhabditis elegans. Biosci Biotechnol Biochem; 2010;74(12):2497-500
SciCrunch. WormBase: Data: Gene Expression .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During the larva-to-adult transition of the nematode Caenorhabditis elegans, expression of the Alzheimer's amyloid precursor protein-like gene, apl-1, is temporally regulated in seam cells.
  • Here we describe a critical cis-regulatory element of apl-1 transcription.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21150118.001).
  • [ISSN] 1347-6947
  • [Journal-full-title] Bioscience, biotechnology, and biochemistry
  • [ISO-abbreviation] Biosci. Biotechnol. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / APL-1 protein, C elegans; 0 / Caenorhabditis elegans Proteins; 0 / DNA-Binding Proteins; 0 / Membrane Proteins; 0 / Transcription Factors; 0 / nuclear hormone receptor NHR-25, C elegans
  •  go-up   go-down


26. Kim MJ, Yoon HS, Cho SY, Lee HJ, Suh JT, Lee J, Yoon HJ, Lee WI, Park TS: ider(17)(q10)t(15;17) associated with relapse and poor prognosis in a pediatric patient with acute promyelocytic leukemia. Cancer Genet Cytogenet; 2010 Sep;201(2):116-21
Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ider(17)(q10)t(15;17) associated with relapse and poor prognosis in a pediatric patient with acute promyelocytic leukemia.
  • Although acute promyelocytic leukemia (APL) has been regarded as a serious medical emergency associated with disseminated intravascular coagulopathy or subsequent mortality, it is now considered a curable leukemia that is particularly sensitive to treatment with all-trans retinoic acid combined with chemotherapy.
  • However, it is not clear whether additional chromosomal abnormalities in APL patients directly influence the prognosis or treatment response. ider(17)(q10)t(15;17)(q22;q21) has mostly been reported in adult APL patients, and only three cases of pediatric APL associated with ider(17)(q10)t(15;17) showing poor prognosis have been described in the literature.
  • Here, we report the close follow-up (clinical and laboratory) data of a pediatric APL case associated with ider(17)(q10)t(15;17).
  • This patient had APL relapse from the same clone 15 months after morphological remission.
  • Furthermore, despite subsequent chemotherapy, the patient died 16 months after the initial APL diagnosis.
  • Although based on a limited amount of data (four pediatric APL cases), such results in pediatric APL patients may provide important insight into the relationship between ider(17)(q10)t(15;17) and poor prognosis.
  • However, further well-designed case-control studies are necessary to determine the treatment response and prognosis in pediatric or adult APL patients with ider(17)(q10)t(15;17).
  • [MeSH-major] Chromosomes, Human, Pair 15. Chromosomes, Human, Pair 17. Leukemia, Promyelocytic, Acute / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20682396.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / Receptors, Retinoic Acid; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor alpha; 143220-95-5 / PML protein, human
  •  go-up   go-down


27. Sino-US Shanghai Leukemia Cooperative Group: [Distribution of WHO subtypes, initial treatment outcomes and prognosis study of 623 unselected adult patients with acute myeloid leukaemia in Shanghai.]. Zhonghua Xue Ye Xue Za Zhi; 2010 Feb;31(2):102-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Distribution of WHO subtypes, initial treatment outcomes and prognosis study of 623 unselected adult patients with acute myeloid leukaemia in Shanghai.].
  • OBJECTIVE: To investigate the current status of acute myeloid leukemia (AML) treatment in Shanghai.
  • METHODS: From 2003 to 2007, a total of successive 623 patients with adult AML were diagnosed and classified according to WHO criteria.
  • The CR rate was 87.3% (68/79), 61.8% (189/306) and 42.9% (48/112) in favorable (excluding APL), intermediate and adverse cytogenetic risk groups, respectively.
  • The CR rate of APL was 91.3%.
  • [MeSH-minor] Adult. China. Humans. Leukemia, Myeloid, Acute / drug therapy. Prognosis. Treatment Outcome

  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20302797.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine
  • [Investigator] Wang XQ
  •  go-up   go-down


28. Simorangkir DR, Marshall GR, Plant TM: A re-examination of proliferation and differentiation of type A spermatogonia in the adult rhesus monkey (Macaca mulatta). Hum Reprod; 2009 Jul;24(7):1596-604
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A re-examination of proliferation and differentiation of type A spermatogonia in the adult rhesus monkey (Macaca mulatta).
  • METHODS: Adult male rhesus monkeys (n = 4) received an i.v. bolus of 5-bromo-2'-deoxyuridine (BrdU): one testis (first) was removed 3 h later and the remaining testis (second) was removed after 11 days and 3 h.
  • Apl (nuclear dia., 8.8 +/- 0.5 microm) appeared in Stages IV-VI and were maximal in Stages VII-X when S-phase labeling of this phenotype at 3 h was greatest.
  • In the second testis, labeled Aps (and Apl) were observed.

  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Androl. 2002 Nov-Dec;23(6):799-805 [12399525.001]
  • [Cites] Endocr Rev. 2001 Dec;22(6):764-86 [11739331.001]
  • [Cites] Am J Anat. 1969 Sep;126(1):57-71 [4982042.001]
  • [Cites] Physiol Rev. 1972 Jan;52(1):198-236 [4621362.001]
  • [Cites] Am J Anat. 1973 Feb;136(2):153-65 [4684877.001]
  • [Cites] Int J Androl. 1983 Feb;6(1):25-43 [6840878.001]
  • [Cites] Biol Reprod. 1986 Aug;35(1):199-207 [3741951.001]
  • [Cites] Biol Reprod. 1986 Oct;35(3):587-91 [3790660.001]
  • [Cites] Biol Reprod. 1996 Jun;54(6):1192-9 [8724345.001]
  • [Cites] Cell Tissue Res. 1997 May;288(2):365-9 [9082972.001]
  • [Cites] Am J Anat. 1959 Mar;104:237-73 [13810669.001]
  • [Cites] Biol Reprod. 2005 Feb;72(2):293-300 [15355878.001]
  • [Cites] Hum Reprod. 2005 May;20(5):1185-93 [15705623.001]
  • [Cites] Biol Reprod. 2005 Dec;73(6):1109-15 [16079304.001]
  • [Cites] Hum Reprod. 2009 Jul;24(7):1584-95 [19279035.001]
  • [Cites] Endocrinology. 2000 Jan;141(1):18-27 [10614619.001]
  • [Cites] J Androl. 2000 Nov-Dec;21(6):776-98 [11105904.001]
  • [Cites] Am J Anat. 1966 Mar;118(2):509-24 [5917196.001]
  • (PMID = 19282325.001).
  • [ISSN] 1460-2350
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / U54 HD 08610
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; G34N38R2N1 / Bromodeoxyuridine
  • [Other-IDs] NLM/ PMC2698324
  •  go-up   go-down


29. Ades L, Chevret S, De Botton S, Thomas X, Dombret H, Beve B, Sanz M, Guerci A, Miguel JS, Dela Serna J, Garo C, Stoppa AM, Reman O, Stamatoulas A, Fey M, Cahn JY, Sotto JJ, Bourhis JH, Parry A, Chomienne C, Degos L, Fenaux P, European APL Group: Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience. Leukemia; 2005 Feb;19(2):230-3
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience.
  • We analyzed the outcome of patients aged more than 60 included in a multicenter trial in newly diagnosed acute promyelocytic leukemia (APL93 trial), which tested the role of early addition of chemotherapy to all trans retinoic acid (ATRA) and of maintenance with ATRA and/or low-dose chemotherapy.
  • The 4-year incidence of relapse was 15.6% in adults older than 60 and 23.2% in younger adults although most elderly patients received less intensive consolidation chemotherapy.
  • APL in elderly patients appears as sensitive to ATRA-Chemotherapy based regimen as in younger adults.
  • Less favorable outcome is mainly due to an increase of early deaths and to toxicity of consolidation treatment, strongly suggesting a beneficial role for less intensive consolidation chemotherapy and possibly introduction of arsenic derivates in the treatment of APL in the elderly.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Europe. Female. Humans. Male. Middle Aged. Recurrence. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15565164.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


30. Citak FE, Ezer U, Akkaya E, Ozbulbul N, Bahce M, Kurekci AE: All-trans-retinoic acid-induced myositis in a child with acute promyelocytic leukemia. Haematologica; 2006 Aug;91(8 Suppl):ECR35
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] All-trans-retinoic acid-induced myositis in a child with acute promyelocytic leukemia.
  • Anthracyclin-based regimens and all-transretinoic acid (ATRA, tretinoin) as differentiating agent are commonly utilized for the treatment of acute promylelocytic leukemia (APL).
  • There are many adverse effects that may be seen during the use of ATRA in patients with APL.
  • Of these, ATRA-induced myositis is rarely described in adults and rare in the children with APL.
  • Herein, we report an 11-year-old girl with APL who developed ATRA-induced myositis during induction treatment.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Promyelocytic, Acute / complications. Myositis / chemically induced. Tretinoin / adverse effects
  • [MeSH-minor] Adult. Child. Female. Humans

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Genetic Alliance. consumer health - Myositis.
  • MedlinePlus Health Information. consumer health - Myositis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923519.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


31. Matsubayashi H, Sugi T, Arai T, Shida M, Kondo A, Suzuki T, Izumi S, McIntyre JA: IgG-antiphospholipid antibodies in follicular fluid of IVF-ET patients are related to low fertilization rate of their oocytes. Am J Reprod Immunol; 2006 May;55(5):341-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PROBLEM: Patients undergoing in vitro fertilization and embryo transfer (IVF-ET) failures show an increased incidence of antiphospholipid antibodies (aPL) in their blood.
  • The physiological manifestations of aPL in this patient group are nonetheless controversial.
  • Pathological effects of aPL on embryos in vitro have been documented.
  • We questioned whether aPL if found in follicular fluids (FFs) could result in embryonic damage.
  • METHOD OF STUDY: Blood from 44 patients with three or more IVF-ET failures were tested by enzyme-linked immunosorbent assays (ELISA) for the presence of immunoglobulin (Ig)G, IgM and IgA aPL.
  • Both the 29 aPL-positive and 15 aPL-negative patients gave permission for FF collection during their next IVF-ET attempt for additional aPL determinations.
  • RESULTS: Patients with no aPL in their blood, had no aPL in their FFs.
  • Patients with IgG and/or IgM aPL in their blood had IgG but not IgM in their respective FFs.
  • CONCLUSIONS: The presence of IgG aPL in FFs and increased infertility length were significantly related to lower fertilization rates, independently.
  • Follicular fluid IgG aPL appears as a risk factor in association with successful IVF-ET outcomes.
  • [MeSH-minor] Adult. Embryo Transfer. Female. Humans. Immunoglobulin G / metabolism. Immunoglobulin M / metabolism. Infertility, Female / immunology. Infertility, Female / therapy. Middle Aged. Oocytes / immunology. Risk Factors. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Reprod Immunol. 2007 Mar;57(3):232
  • (PMID = 16635208.001).
  • [ISSN] 1046-7408
  • [Journal-full-title] American journal of reproductive immunology (New York, N.Y. : 1989)
  • [ISO-abbreviation] Am. J. Reprod. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Immunoglobulin G; 0 / Immunoglobulin M
  •  go-up   go-down


32. Roy S, Mehta V, Suri R, Rath G, Dhuria R, Das S: Bitendinous insertion of abductor pollicis longus coexistent with a rare accessory antebrachial muscle: clinico-anatomical considerations. Clin Ter; 2010;161(2):159-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reports of the anomalous orientation of the musculature of the fi rst osseofi brous extensor compartment of the wrist are not uncommon; especially that of Abductor Pollicis Longus (APL) muscle.
  • In this report, we highlight a unique variation in the APL muscle of the left side in an adult male cadaver.
  • The present anomaly consisted of a bitendinous insertion of APL on the base of the fi rst metacarpal, complemented by an additional muscle belly arising from the fascia covering Extensor Carpi Radialis Longus (ECRL).
  • Such multiple tendons of APL are benefi cial clinically in providing additive support to the fi rst carpo-metacarpal joint and act as effective aids in tendon transfers and reconstructive procedures of the hand.
  • Thus, it is imperative for surgeons and clinicians to acquire a prior substantial knowledge of such anatomical variants of APL before attempting any treatment of this region.
  • [MeSH-minor] Adult. Cadaver. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20499032.001).
  • [ISSN] 1972-6007
  • [Journal-full-title] La Clinica terapeutica
  • [ISO-abbreviation] Clin Ter
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


33. Mrózek K, Bloomfield CD: Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia. J Natl Cancer Inst Monogr; 2008;(39):52-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia.
  • Acquired genetic alterations such as balanced and unbalanced chromosome aberrations and submicroscopic gene mutations and changes in gene expression strongly affect pretreatment features and prognosis of adults with acute myeloid leukemia (AML).
  • The most frequent chromosome/molecular rearrangements, that is, t(8;21)(q22;q22)/RUNX1-RUNX1T1 and inv(16)(p13q22)/t(16;16)(p13;q22)/CBFB-MYH11 characteristic of core-binding factor (CBF) AML and t(15;17)(q22;q12-21)/PML-RARA characteristic of acute promyelocytic leukemia (APL), confer favorable clinical outcome when patients receive optimal treatment, that is, regimens that include high-dose cytarabine for CBF AML and all-trans-retinoic acid and/or arsenic trioxide for APL.
  • Recently, mutations in such genes as KIT in CBF AML and FLT3 in APL have been correlated with clinical features and/or outcome of patients with these AML subtypes, and microarray gene expression profiling has been successfully used for diagnostic purposes and to provide biologic insights.
  • These data underscore the value of genetic testing for common translocations for diagnosis, prognostication, and, increasingly, selecting therapy in acute leukemia.
  • [MeSH-major] Chromosomes, Human / genetics. Leukemia, Myeloid, Acute / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Chromosome Inversion. Core Binding Factors / genetics. Humans

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18648004.001).
  • [ISSN] 1052-6773
  • [Journal-full-title] Journal of the National Cancer Institute. Monographs
  • [ISO-abbreviation] J. Natl. Cancer Inst. Monographs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA101140; United States / NCI NIH HHS / CA / CA16058
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factors
  •  go-up   go-down


34. Sun HM, Qian SX, Wu YJ, Qiao C, Hong M, Fan L, Yang H, Zhang JF, Zhang SJ, Wu HX, Qiu HX, Lu H, Xu W, Sheng RL, Li JY: [Immunophenotypic features in 143 cases of acute promyelocytic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb;17(1):176-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunophenotypic features in 143 cases of acute promyelocytic leukemia].
  • This study was aimed to investigate the immunophenotypic characteristics of acute promyelocytic leukemia (APL).
  • CD45/Side Scatter (SSC) gating strategy and multiparametric flow cytometry were used to determine immunophenotype of 143 patients with APL.
  • The immunophenotypic features were compared between newly diagnosed APL patients and relapsed APL patients.
  • 42 patients with HLA-DR(-) (non-APL AML, DR(-)AML) were randomly selected as controls.
  • 31 out of 42 AML patients were CD34 negative, and their immunophenotypes were compared with those in newly diagnosed APL patients.
  • The results showed that (1) CD34 and HLA-DR were both negative in 91.9% of newly diagnosed APL, while the positive rate of CD34 and HLA-DR elevated in relapsed cases (3.0% vs 37.5%, 3.9% vs 37.5%).
  • The positive rate of CD34 in HLA-DR(-) AML group was higher than that in newly diagnosed APL group (23.4% vs 3.0%).
  • The positive level of CD34 in newly diagnosed APL group was lower than that in HLA-DR(-) AML group;.
  • (2) the positive rate of CD33 in newly diagnosed APL group was higher than that in other groups (97.0% vs 75.0%, 83.3%, 83.9%), as well as the the positive level of CD33 (p < 0.05). (3) no lymphoid antigen other than CD2 was expressed in newly diagnosed APL group.
  • The positive rate of CD7 was 9.5% in DR(-) AML group and 6.5% in CD34(-)/DR(-) AML group, both were higher than those of newly diagnosed APL group (p < 0.05).
  • It is concluded that the immunophenotyping can provide proof to the rapid diagnosis of APL.
  • For those patients with DR(-) AML, it may be helpful to identify APL depending on following features: low or negative CD34 expression, homogeneous and bright expression of CD33, no lymphoid antigens other than CD2, higher SSC.

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19236773.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / HLA-DR Antigens; 0 / Sialic Acid Binding Ig-like Lectin 3
  •  go-up   go-down


35. Tennent-Brown BS, Wilkins PA, Lindborg S, Russell G, Boston RC: Assessment of a point-of-care lactate monitor in emergency admissions of adult horses to a referral hospital. J Vet Intern Med; 2007 Sep-Oct;21(5):1090-8
Hazardous Substances Data Bank. LACTIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of a point-of-care lactate monitor in emergency admissions of adult horses to a referral hospital.
  • ANIMALS: The study included adult horses presented for emergency evaluation.
  • [LAC] was measured with whole blood (AWB) and plasma (APL) by means of a POC monitor (Accutrend) and compared with results from whole blood measured by a laboratory blood gas analyzer (NOVA).
  • Agreement (p +/- SE) was closest between APL and NOVA (0.97 +/- 0.01); an average observed difference of 0.15 +/- 0.89 (mean +/- SD) and 95% limits of agreement (LOA) -1.89, 1.59 also were found.

  • MedlinePlus Health Information. consumer health - Emergency Medical Services.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17939569.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 33X04XA5AT / Lactic Acid
  •  go-up   go-down


36. Kim MJ, Cho SY, Kim MH, Lee JJ, Kang SY, Cho EH, Huh J, Yoon HJ, Park TS, Lee WI, Marschalek R, Meyer C: FISH-negative cryptic PML-RARA rearrangement detected by long-distance polymerase chain reaction and sequencing analyses: a case study and review of the literature. Cancer Genet Cytogenet; 2010 Dec;203(2):278-83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FISH-negative cryptic PML-RARA rearrangement detected by long-distance polymerase chain reaction and sequencing analyses: a case study and review of the literature.
  • Although a normal karyotype according to conventional cytogenetic analysis in association with cryptic t(15;17) has been infrequently reported in cases of acute promyelocytic leukemia (APL), a fluorescence in situ hybridization (FISH)-negative cryptic PML-RARA rearrangement is even more rare, with only 12 such APL cases of FISH-negative cryptic PML-RARA rearrangements in the literature.
  • Reported here is an additional clinical APL case with a FISH-negative cryptic PML-RARA rearrangement, confirmed by long-distance DNA polymerase chain reaction method.
  • [MeSH-minor] Adolescent. Adult. Chromosomes / ultrastructure. Female. Genome, Human. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [CommentIn] Ann Hematol. 2012 Oct;91(10):1645-8 [22402611.001]
  • (PMID = 21156244.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
  •  go-up   go-down


37. Boban A, Radman I, Zadro R, Dubravcic K, Maretic T, Civljak R, Lisic M, Begovac J: Acute promyelocytic leukemia after whole brain irradiation of primary brain lymphoma in an HIV-infected patient. Eur J Med Res; 2009 Jan 28;14(1):42-3
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute promyelocytic leukemia after whole brain irradiation of primary brain lymphoma in an HIV-infected patient.
  • The occurrence of acute promyelocytic leukemia (APL) in HIV-infected patients has been reported in only five cases.
  • Due to a very small number of reported HIV/APL patients who have been treated with different therapies with the variable outcome, the prognosis of APL in the setting of the HIV-infection is unclear.
  • Here, we report a case of an HIV-patient who developed APL and upon treatment entered a complete remission.
  • In 2006, prompted by a sudden neutropenia, we carried out a set of diagnostic procedures, revealing APL.
  • The last follow-up 14 months later, showed sustained molecular APL remission.
  • In conclusion, we demonstrated that a complete molecular APL remission in an HIV-patient was achieved by using reduced-intensity treatment.
  • [MeSH-major] Brain / radiation effects. Brain Neoplasms / radiotherapy. HIV Infections / complications. Leukemia, Promyelocytic, Acute / etiology. Leukemia, Radiation-Induced / etiology. Lymphoma / radiotherapy
  • [MeSH-minor] Adult. Anti-Retroviral Agents / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Antiretroviral Therapy, Highly Active / methods. Bisexuality. Humans. Idarubicin / therapeutic use. Male. Remission Induction. Tretinoin

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2001 Mar;112(4):900-8 [11298584.001]
  • [Cites] J Clin Oncol. 2003 Jun 1;21(11):2123-37 [12775738.001]
  • [Cites] Hematology. 2007 Jun;12(3):263-6 [17558705.001]
  • [Cites] Leuk Lymphoma. 1997 Aug;26(5-6):621-4 [9389370.001]
  • [Cites] Am J Hematol. 2006 Apr;81(4):300 [16550512.001]
  • [Cites] Am J Hematol. 2004 Nov;77(3):287-90 [15495246.001]
  • (PMID = 19258210.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / Antibiotics, Antineoplastic; 5688UTC01R / Tretinoin; ZRP63D75JW / Idarubicin
  • [Other-IDs] NLM/ PMC3352204
  •  go-up   go-down


38. Adkison KK, Shachoy-Clark A, Fang L, Lou Y, Otto VR, Berrey MM, Piscitelli SC: The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects. Br J Clin Pharmacol; 2006 Sep;62(3):336-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: This study assessed the effects of the CYP3A inhibitors lopinavir/ritonavir (LPV/r) on the steady-state pharmacokinetics (PK) of aplaviroc (APL), a CYP3A4 substrate, in healthy subjects.
  • METHODS: In Part 1, APL PK was determined in eight subjects who received a single oral 50-mg APL test dose with/without a single dose of 100 mg ritonavir (RTV).
  • Subjects received APL 400 mg every 12 h (b.i.d.) for 7 days (Period 1), LPV/r 400/100 mg b.i.d. for 14 days (Period 2) and APL 400 mg + LPV/r 400/100 mg b.i.d. for 7 days (Period 3).
  • RESULTS: In Part 1, a single RTV dose increased the APL AUC(0-infinity) by 2.1-fold [90% confidence interval (CI) 1.9, 2.4].
  • Repeat dose coadministration of APL with LPV/r increased APL exposures to a greater extent with the geometric least squares mean ratios (90% CI) being 7.7 (6.4, 9.3), 6.2 (4.8, 8.1) and 7.1 (5.6, 9.0) for the APL AUC, C(max), and C(min), respectively.
  • The combination of APL and LPV/r was well tolerated and adverse events were mild in severity with self-limiting gastrointestinal complaints most commonly reported.
  • CONCLUSIONS: Coadministration of APL and LPV/r was well tolerated and resulted in significantly increased APL plasma concentrations.
  • [MeSH-minor] Adolescent. Adult. Animals. Benzoates / pharmacokinetics. Drug Combinations. Drug Interactions. Female. Humans. Lopinavir. Male. Mice. Middle Aged. Piperazines / pharmacokinetics. Rats. Spiro Compounds / pharmacokinetics

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Clin Pharmacol. 2001 Sep;52(3):255-64 [11560557.001]
  • [Cites] HIV Med. 2001 Apr;2(2):105-13 [11737387.001]
  • [Cites] J Pharm Sci. 2001 Nov;90(11):1829-37 [11745741.001]
  • [Cites] Drugs. 2003;63(8):769-802 [12662125.001]
  • [Cites] Clin Pharmacol Ther. 2003 Nov;74(5):437-47 [14586384.001]
  • [Cites] Clin Pharmacokinet. 2004;43(5):291-310 [15080763.001]
  • [Cites] AIDS. 2005 Sep 23;19(14):1443-8 [16135896.001]
  • [Cites] Clin Pharmacol Ther. 1998 Apr;63(4):453-64 [9585800.001]
  • [Cites] Clin Pharmacokinet. 1998 Oct;35(4):275-91 [9812178.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Feb;312(2):583-91 [15523003.001]
  • [Cites] Mol Pharmacol. 2005 Apr;67(4):1268-82 [15644495.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Jul;49(7):2802-6 [15980352.001]
  • [Cites] Rev Med Virol. 2004 Jul-Aug;14(4):255-70 [15248253.001]
  • (PMID = 16934050.001).
  • [ISSN] 0306-5251
  • [Journal-full-title] British journal of clinical pharmacology
  • [ISO-abbreviation] Br J Clin Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzoates; 0 / CCR5 Receptor Antagonists; 0 / Drug Combinations; 0 / Piperazines; 0 / Pyrimidinones; 0 / Spiro Compounds; 2494G1JF75 / Lopinavir; 98B425P30V / aplaviroc; O3J8G9O825 / Ritonavir
  • [Other-IDs] NLM/ PMC1885134
  •  go-up   go-down


39. Kalashnikova LA, Dobrynina LA, Aleksandrova EN, Novikov AA: [Neurological appearances of primary antiphospholipid syndrome]. Zh Nevrol Psikhiatr Im S S Korsakova; 2005;(Suppl 13):19-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One hundred and twenty four patients (100 women, 24 men, mean age 37.5 +/- 11.3 years) with primary APS (PAPS), including 76 patients with Sneddon's syndrome and positive antibodies to phospholipids (aPL), have been studied.
  • A structure of neurological disturbances was as follows: ischemic lesions of cerebral blood flow (LCBF) which comprised stroke and transient LCBF (91%); thrombosis of brain venous sinuses (3%); epileptic seizures (24%); headache (65%); chorea (15%); visual neuropathy (9%); peripheral neuropathy (6%); multiple-sclerosis-like syndrome (10%); myasthenia syndrome (1%); syndrome of parkinsonism of non-vascular genesis (1%) and psychotic disorders (2%).
  • All the patients had aPL: aPL to cardiolipin (aCL) and/or lupus coagulant (LC) and/or aPL to phosphatidyl serine, phosphatidyl inositol, phosphatidyl ethanolamine.
  • Thus, the presence of clinical symptoms of PAPS including neurological disturbances demands an investigation of different aPL types as well as a replicate study for immunological confirmation of PAPS.

  • Genetic Alliance. consumer health - Antiphospholipid Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15986822.001).
  • [ISSN] 1997-7298
  • [Journal-full-title] Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
  • [ISO-abbreviation] Zh Nevrol Psikhiatr Im S S Korsakova
  • [Language] RUS
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antibodies, Anticardiolipin; 0 / Antibodies, Antiphospholipid
  •  go-up   go-down


40. Kawakami T, Yamazaki M, Mizoguchi M, Soma Y: High titer of serum antiphospholipid antibody levels in adult Henoch-Schönlein purpura and cutaneous leukocytoclastic angiitis. Arthritis Rheum; 2008 Apr 15;59(4):561-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High titer of serum antiphospholipid antibody levels in adult Henoch-Schönlein purpura and cutaneous leukocytoclastic angiitis.
  • OBJECTIVE: To investigate a possible role of antiphospholipid (aPL) antibodies in adult Henoch-Schönlein purpura (HSP) and cutaneous leukocytoclastic angiitis (CLA).
  • In contrast, aPL antibodies were not found in any MPA patients or normal controls.
  • CONCLUSION: Serum levels of IgA aCL and anti-PS/PT antibodies were elevated in adult HSP, suggesting that serum IgA antibodies may play some role in adult HSP.
  • IgA aCL and/or anti-PS/PT antibodies could serve as markers for adult HSP and should be monitored as an indicator of adult HSP activity.
  • These findings suggest that aPL antibodies are closely related to the pathogenic factors that trigger the development of vasculitis.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Henoch-Schonlein purpura.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18383424.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid
  •  go-up   go-down


41. Imagawa J, Harada Y, Shimomura T, Tanaka H, Okikawa Y, Hyodo H, Kimura A, Harada H: Clinical and genetic features of therapy-related myeloid neoplasms after chemotherapy for acute promyelocytic leukemia. Blood; 2010 Dec 23;116(26):6018-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and genetic features of therapy-related myeloid neoplasms after chemotherapy for acute promyelocytic leukemia.
  • Acute promyelocytic leukemia (APL) is a highly curable disease with excellent complete remission and long-term survival rates.
  • However, the development of therapy-related myeloid neoplasms (t-MN) is being reported with increasing frequency in patients successfully treated for APL.
  • We compared 10 relapse and 11 t-MN cases that developed in 108 patients during their first complete remission from APL.
  • At APL diagnosis, t-MN patients had lower white blood cell counts than did relapse patients (P = .048).
  • The t-MN cases were characterized as CD34(+)/HLA-DR(+) and PML-RARA(-), and 4 RUNX1/AML1 mutations were detected.
  • T-MN is easily distinguished from APL relapse by evaluating these hematologic features, and it may originate from primitive myeloid cells by chemotherapy-induced RUNX1 mutations.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / genetics. Neoplasms, Second Primary / chemically induced. Neoplasms, Second Primary / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. CCAAT-Enhancer-Binding Proteins / genetics. Core Binding Factor Alpha 2 Subunit / genetics. Female. Genes, ras / genetics. Humans. Male. Middle Aged. Mutation / genetics. Prognosis. Risk Factors. Survival Rate. Young Adult. fms-Like Tyrosine Kinase 3 / genetics

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20861459.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Proteins; 0 / CEBPA protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / RUNX1 protein, human; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


42. Adès L, Fenaux P: Is cytarabine required in the treatment of acute promyelocytic leukemia? Curr Hematol Malig Rep; 2006 Jun;1(2):122-5
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is cytarabine required in the treatment of acute promyelocytic leukemia?
  • Until the late 1980s, chemotherapy with anthracyclines and cytarabine (AraC) was the only treatment approach for acute promyelocytic leukemia (APL), as for other types of acute myeloid leukemia.
  • Many studies have shown that treatment with all-trans retinoic acid (ATRA), followed by anthracycline-AraC chemotherapy, significantly decreases the incidence of relapse and improves survival in newly diagnosed APL, compared with this chemotherapy alone.
  • Several groups have reported high rates of complete remission and low rates of relapse with ATRA and chemotherapy using anthracyclines alone, suggesting that AraC could be avoided in the chemotherapy of APL, reducing toxicity.
  • These results were not confirmed in other studies, however, raising the issue of the role of AraC in treatment of patients with newly diagnosed APL.
  • [MeSH-major] Cytarabine / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy
  • [MeSH-minor] Adult. Anthracyclines / administration & dosage. Anthracyclines / adverse effects. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Humans. Middle Aged. Multicenter Studies as Topic. Randomized Controlled Trials as Topic. Remission Induction. Treatment Outcome. Tretinoin / administration & dosage. Tretinoin / adverse effects

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1995 Sep 1;86(5):1717-28 [7655004.001]
  • [Cites] Leukemia. 1992;6 Suppl 1:64-6 [1548938.001]
  • [Cites] Cancer. 1997 Dec 1;80(11 Suppl):2181-5 [9395031.001]
  • [Cites] Semin Hematol. 1996 Oct;33(4 Suppl 3):12-7 [8916311.001]
  • [Cites] Blood. 1993 Dec 1;82(11):3241-9 [8241496.001]
  • [Cites] Blood. 1992 Feb 1;79(3):543-53 [1732003.001]
  • [Cites] Leuk Lymphoma. 1991;4(4):239-48 [27463043.001]
  • [Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]
  • [Cites] Cell. 1991 Aug 23;66(4):675-84 [1652369.001]
  • [Cites] N Engl J Med. 1991 May 16;324(20):1385-93 [1850498.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1237-43 [14576047.001]
  • [Cites] Blood. 1998 Oct 15;92(8):2712-8 [9763554.001]
  • [Cites] Blood. 1989 Apr;73(5):1116-22 [2930837.001]
  • [Cites] Blood. 2010 Oct 28;116(17):3171-9 [20644121.001]
  • [Cites] Blood. 1988 Aug;72(2):567-72 [3165295.001]
  • [Cites] Leukemia. 1994;8 Suppl 2:S38-41 [7815835.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1192-200 [10438706.001]
  • [Cites] Am J Med. 1984 May;76(5):827-41 [6586073.001]
  • [Cites] Leukemia. 2005 Feb;19(2):230-3 [15565164.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):483-90 [9053469.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3141-6 [12384411.001]
  • [Cites] Nouv Rev Fr Hematol. 1984;26(6):371-8 [6597407.001]
  • [Cites] Ann Intern Med. 1992 Aug 15;117(4):292-6 [1637024.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1247-53 [10942364.001]
  • [Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]
  • (PMID = 20425342.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin
  • [Number-of-references] 26
  •  go-up   go-down


43. Mok MY, Chan EY, Fong DY, Leung KF, Wong WS, Lau CS: Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus. J Rheumatol; 2005 Apr;32(4):622-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Different prevalences of antiphospholipid antibodies (aPL) have been reported in different populations of patients with systemic lupus erythematosus (SLE).
  • We examined the prevalence of aPL including lupus anticoagulant (LAC), anticardiolipin (aCL) and anti-beta2-glycoprotein I (anti-beta2-GPI) antibodies, the level of thrombotic risk, and the association of aPL with thrombotic and pregnancy outcomes in a Chinese cohort with SLE at the university lupus clinic during the period 1986-2003.
  • METHODS: aPL were measured in 272 SLE patients, and medical records were reviewed for vascular thrombosis and pregnancy outcomes.
  • All aPL were shown to be associated with vascular thrombosis.
  • Patients taking hydroxychloroquine were found to have fewer thrombotic complications than those who were not (OR 0.17, 95% CI 0.07-0.44; p < 0.0001).
  • CONCLUSION: The lifetime and recurrent thrombotic rates in our patients with aPL were not particularly different from those in the literature.
  • However, the lower prevalence of aPL in our cohort may suggest a role of other prothrombotic factors in predisposition to thrombosis.
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Hong Kong / epidemiology. Hospitals, University. Humans. Longitudinal Studies. Male. Middle Aged. Pregnancy


44. Lampropoulos CE, Koutroumanidis M, Reynolds PP, Manidakis I, Hughes GR, D'Cruz DP: Electroencephalography in the assessment of neuropsychiatric manifestations in antiphospholipid syndrome and systemic lupus erythematosus. Arthritis Rheum; 2005 Mar;52(3):841-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fourteen patients had APS, 24 patients were positive for antiphospholipid antibodies (aPL), and 19 patients had SLE without aPL.
  • Abnormal EEG findings were observed in all patients with APS and in 17 of 24 aPL-positive patients (71%), compared with 6 of 19 patients with SLE (32%) (P < 0.001 and P < 0.05, respectively).
  • There was an association between abnormal EEG findings and the frequency of aPL positivity (at least 2 positive results) (P = 0.002).
  • Results of brain MRI were abnormal in 18 (31.6%) of 57 patients: 8 in the APS group (57.1%), 7 in the aPL-positive group (29.2%), and 3 in the SLE group (15.8%).
  • CONCLUSION: Our findings suggest that EEG abnormalities are common and correlate with the presence of aPL even in the absence of brain abnormalities on MRI.
  • EEG should be considered in aPL-positive patients with neuropsychiatric symptoms, because use of antiaggregants or anticoagulation may need to be considered.
  • [MeSH-minor] Adult. Antibodies, Antiphospholipid / immunology. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neuropsychological Tests. Prevalence


45. Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, Paoloni F, Fioritoni G, Ferrara F, Specchia G, Cimino G, Diverio D, Borlenghi E, Martinelli G, Di Raimondo F, Di Bona E, Fazi P, Peta A, Bosi A, Carella AM, Fabbiano F, Pogliani EM, Petti MC, Amadori S, Mandelli F, Italian GIMEMA Cooperative Group: Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood; 2010 Oct 28;116(17):3171-9
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group.
  • After the identification of discrete relapse-risk categories in patients with acute promyelocytic leukemia (APL) receiving all-trans retinoic and idarubicin (AIDA)-like therapies, the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) designed a protocol for newly diagnosed APL (AIDA-2000) in which postremission treatment was risk-adapted.
  • In addition, all patients in the AIDA-2000 received all-trans retinoic acid (ATRA) for 15 days during each consolidation.
  • Our data confirm that anthracycline-based consolidation is at least equally effective as cytarabine-containing regimens for low-/intermediate-risk patients and suggest that a risk-adapted strategy including ATRA for consolidation improves outcome in newly diagnosed APL.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Idarubicin / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Anthracyclines / administration & dosage. Anthracyclines / therapeutic use. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / therapeutic use. Cytarabine / administration & dosage. Cytarabine / therapeutic use. Humans. Middle Aged. Remission Induction. Young Adult

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20644121.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT01064570
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin; ZRP63D75JW / Idarubicin
  •  go-up   go-down


46. Dimov ND, Medeiros LJ, Kantarjian HM, Cortes JE, Chang KS, Bueso-Ramos CE, Ravandi F: Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients. Cancer; 2010 Jan 15;116(2):369-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients.
  • BACKGROUND: The authors evaluated the utility of immunofluorescence staining with an antipromyelocytic leukemia (anti-PML) antibody for patients with a suspected diagnosis of new or relapsed acute promyelocytic leukemia (APL) and correlated the findings with the results of other established diagnostic modalities.
  • METHODS: Bone marrow (BM) and/or peripheral blood (PB) smears from 349 patients in whom the diagnosis of APL was considered were assessed with the anti-PML antibody using immunofluorescence.
  • The study group included 199 patients with confirmed APL and 150 with other conditions.
  • The results of conventional cytogenetics, reverse transcription polymerase chain reaction (RT-PCR), and fluorescence in situ hybridization (FISH) performed on these patients were correlated with the PML results.
  • RESULTS: Among patients with confirmed APL, anti-PML antibody was positive in 182 of 184 BM and 32 of 33 PB smears.
  • Conventional cytogenetics demonstrated t(15;17)(q22;q12) in 166 of 182 (91%) patients; 10 had a normal karyotype, 4 had insufficient mitoses to grow in culture, 1 was inconclusive, and 1 was 48, XX, +8, +8.
  • Anti-PML staining was positive in 9 of 10 with a normal karyotype and in all 4 cases with insufficient mitoses.
  • RT-PCR and FISH were positive for PML-retinoic acid receptor-alpha in 169 of 172 (98%) and 90 of 94 (96%) cases, respectively.
  • Among the patients without APL, 148 of 150 (98.6%) were negative with anti-PML antibody.
  • CONCLUSIONS: PML immunofluorescence staining is a rapid (<4 hours turnaround time) and reliable frontline diagnostic approach that can facilitate initiation of targeted therapy, particularly in clinical settings where cytogenetic and molecular testing are not readily available.
  • [MeSH-major] Antibodies, Neoplasm. Fluorescent Antibody Technique / methods. Leukemia, Promyelocytic, Acute / diagnosis. Nuclear Proteins. Transcription Factors. Tumor Suppressor Proteins
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. In Situ Hybridization, Fluorescence. Infant. Karyotyping. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2007 Mar;92(3):315-22 [17339180.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:156-61, 514 [17124055.001]
  • [Cites] Curr Protoc Hum Genet. 2001 May;Appendix 4:Appendix 4B [18428229.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):504-10 [19075265.001]
  • [Cites] Blood. 2009 Feb 26;113(9):1875-91 [18812465.001]
  • [Cites] Cytometry. 2000 Apr 15;42(2):106-9 [10797447.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2505-15 [18299451.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1287-96 [10942370.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1297-308 [10942371.001]
  • [Cites] Am J Clin Pathol. 2000 Nov;114(5):786-92 [11068554.001]
  • [Cites] Semin Hematol. 2001 Jan;38(1):4-12 [11172535.001]
  • [Cites] Am J Clin Pathol. 2002 Apr;117(4):651-7 [11939742.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Mar;6(1):60-71; discussion 86-7 [12060484.001]
  • [Cites] Biochem Cell Biol. 2002;80(3):301-10 [12123283.001]
  • [Cites] Mol Cell Biol. 2003 Jun;23(12):4247-56 [12773567.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):1022-9 [14608536.001]
  • [Cites] Am J Clin Pathol. 2004 Mar;121(3):402-7 [15023045.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2819-24 [15077145.001]
  • [Cites] Ann Hematol. 2004 Nov;83(11):687-90 [15278297.001]
  • [Cites] N Engl J Med. 1993 Jul 15;329(3):177-89 [8515790.001]
  • [Cites] Cell. 1994 Jan 28;76(2):333-43 [8293467.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Jan;72(1):73-4 [8111743.001]
  • [Cites] Blood. 1995 Jun 15;85(12):3646-53 [7780148.001]
  • [Cites] Blood. 1995 Aug 1;86(3):862-7 [7620182.001]
  • [Cites] J Biol Chem. 1996 Jan 5;271(1):130-5 [8550548.001]
  • [Cites] Blood. 1997 Nov 15;90(10):4046-53 [9354674.001]
  • [Cites] Am J Hum Genet. 1998 Aug;63(2):297-304 [9683622.001]
  • [Cites] Mol Cell Biol. 1998 Dec;18(12):7147-56 [9819401.001]
  • [Cites] Am J Clin Pathol. 2005 Jun;123(6):840-8 [15899774.001]
  • [Cites] Am J Clin Pathol. 2005 Nov;124(5):807-14 [16203287.001]
  • [CommentIn] Cancer. 2011 Jan 15;117(2):435; author reply 435-6 [20845483.001]
  • (PMID = 19950129.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 143220-95-5 / PML protein, human
  • [Other-IDs] NLM/ NIHMS629441; NLM/ PMC4180261
  •  go-up   go-down


47. Lin J, Han LX, Qian J, Wang YL, Yao DM, Qian Z, Yang XF, Sheng XJ: Expression patterns of specific promyelocytic/retinoic acid receptor-alpha transcripts in patients with acute promyelocytic leukemia. Int J Lab Hematol; 2010 Jun;32(3):344-50
Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression patterns of specific promyelocytic/retinoic acid receptor-alpha transcripts in patients with acute promyelocytic leukemia.
  • Several additional promyelocytic/retinoic acid receptor-alpha (PML/RARalpha) transcripts besides bcr1, bcr2, and bcr3 have been identified in patients with acute promyelocytic leukemia (APL).
  • The real-time quantitative polymerase chain reaction was established to detect each specific isoform of PML/RARalpha transcripts (bcr1/2, P46R3, P4R3, bcr3, and P2R3) in 46 APL patients.
  • We suggest that alternative splicing of PML/RARalpha transcripts might be involved in NMD and each isoform should be quantified to further understand the pathogenesis of APL, stratify the risk of relapse, and monitor minimal residual disease.
  • [MeSH-major] Gene Expression Regulation. Leukemia, Promyelocytic, Acute / metabolism. Nuclear Proteins / metabolism. Receptors, Retinoic Acid / metabolism. Transcription Factors / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD34 / metabolism. Child. Child, Preschool. Female. Gene Expression Profiling. Humans. Immunophenotyping. Male. Middle Aged. Protein Isoforms / genetics. Protein Isoforms / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19863682.001).
  • [ISSN] 1751-553X
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Nuclear Proteins; 0 / Protein Isoforms; 0 / Receptors, Retinoic Acid; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor alpha; 143220-95-5 / PML protein, human
  •  go-up   go-down


48. Yamada H, Atsumi T, Kobashi G, Ota C, Kato EH, Tsuruga N, Ohta K, Yasuda S, Koike T, Minakami H: Antiphospholipid antibodies increase the risk of pregnancy-induced hypertension and adverse pregnancy outcomes. J Reprod Immunol; 2009 Jan;79(2):188-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antiphospholipid antibody (aPL) is associated with thromboembolism.
  • There is scant evidence of a relationship between the aPL profile and serious adverse pregnancy outcome.
  • The aim of this study was to assess whether aPL measurements during early pregnancy were useful in predicting a serious adverse pregnancy outcome.
  • The 99 th percentile cut-off values in each aPL were determined using samples from 105 women who did not exhibit any pregnancy morbidity.
  • The combinations of IgG aPE plus IgG aCL (17.5, 4.7-66.7) or IgG aPE plus LA (22.2, 5.4-909) measurements predicted severe PIH with 30.8% sensitivity and 99.2% specificity.
  • We conclude that aPL measurements during early pregnancy may be useful in predicting adverse pregnancy outcome.
  • [MeSH-minor] Adult. Female. Humans. Multivariate Analysis. Pregnancy. Pregnancy Outcome. Risk Factors

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - High Blood Pressure in Pregnancy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19211151.001).
  • [ISSN] 1872-7603
  • [Journal-full-title] Journal of reproductive immunology
  • [ISO-abbreviation] J. Reprod. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid
  •  go-up   go-down


49. Fox E, Razzouk BI, Widemann BC, Xiao S, O'Brien M, Goodspeed W, Reaman GH, Blaney SM, Murgo AJ, Balis FM, Adamson PC: Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood; 2008 Jan 15;111(2):566-73
Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.
  • Arsenic trioxide (ATO) induces remission in 85% of adults with refractory acute promyelocytic leukemia (APL).
  • We conducted a phase 1 trial of ATO in children (median age 13 y, range, 2-19) with refractory leukemia.
  • Patients with APL (n=13) received 0.15 mg/kg per day, and patients with other types of leukemia received 0.15 mg/kg per day (n=2) or 0.2 mg/kg per day (n=4).
  • At 0.15 mg/kg per day, 2 of 15 patients experienced dose-limiting corrected QT interval (QTc) prolongation, pneumonitis, or neuropathic pain.
  • At 0.15 mg/kg per day, the median (range) plasma arsenic maximum concentration (Cmax) was 0.28 microM (0.11-0.37 microM) and at 0.2 mg/kg per day, Cmax was 0.40 and 0.46 microM; area under the concentration times time curve (AUC0-24) was 2.50 microM-hr (1.28-3.85 microM-hr) and 4.37 microM-hr and 4.69 microM-hr, respectively.
  • Morphologic complete response (CR) was achieved in 85% of patients with APL; no responses were observed in non-APL patients.
  • ATO is well-tolerated in children at the recommended dose of 0.15 mg/kg per day.
  • The response rate in children with relapsed APL is similar to the response rate in adults.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Arsenicals / pharmacokinetics. Leukemia, Promyelocytic, Acute / drug therapy. Lymphoma / drug therapy. Oxides / pharmacokinetics
  • [MeSH-minor] Abdominal Pain / chemically induced. Abdominal Pain / drug therapy. Adolescent. Adult. Child. Child, Preschool. Constipation / chemically induced. Constipation / drug therapy. Dermatitis / drug therapy. Dermatitis / etiology. Dose-Response Relationship, Drug. Female. Headache / chemically induced. Headache / drug therapy. Humans. Hyperglycemia / chemically induced. Hyperglycemia / drug therapy. Infusions, Intravenous. Male. Nausea / chemically induced. Nausea / drug therapy. Pancreatitis / chemically induced. Pancreatitis / drug therapy. Pneumonia / chemically induced. Pneumonia / drug therapy. Recurrence. Time Factors. Vomiting / chemically induced. Vomiting / drug therapy. Water-Electrolyte Balance / drug effects

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 15;94(10):3315-24 [10552940.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2387-401 [15621751.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2620-5 [10893295.001]
  • [Cites] Blood. 2001 Jul 15;98(2):266-71 [11435292.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3852-60 [11559723.001]
  • [Cites] Eur J Clin Pharmacol. 2002 Nov;58(8):521-6 [12451429.001]
  • [Cites] J Environ Sci Health A Tox Hazard Subst Environ Eng. 2003 Jan;38(1):165-83 [12635825.001]
  • [Cites] Cancer. 2003 May 1;97(9):2218-24 [12712474.001]
  • [Cites] J Biol Chem. 2003 Aug 22;278(34):31998-2004 [12767976.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3609-15 [14512391.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4578-83 [15070760.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35 [15044693.001]
  • [Cites] Blood. 2004 May 1;103(9):3496-502 [14701702.001]
  • [Cites] Clin Chem. 1992 Dec;38(12):2479-83 [1458588.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3978-83 [9108090.001]
  • [Cites] Blood. 1997 May 1;89(9):3345-53 [9129041.001]
  • [Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):124-33 [9450572.001]
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1341-8 [9801394.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3053-8 [10397243.001]
  • [Cites] Blood. 1999 Sep 15;94(6):2102-11 [10477740.001]
  • [Cites] Blood. 2000 Jan 1;95(1):90-5 [10607690.001]
  • (PMID = 17959855.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00020111
  • [Grant] United States / NCI NIH HHS / CA / U01 CA097452; United States / NCI NIH HHS / CA / UM1 CA097452; United States / NCI NIH HHS / CA / CA97452; United States / Intramural NIH HHS / /
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  • [Other-IDs] NLM/ PMC2200837
  •  go-up   go-down


50. Lin QD, Wei XD, Wang P, Liu YY, Zhang LN, Li YF, Gao QL, Zhu XH, Zhang YL, Fang BJ, Yue H, Du JW, Jiang DX, Hu JY, Song YP: [Application of all-trans retinoic acid combining chemotherapy and As4S4 in the maintenance treatment of patients with acute promyelocytic leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2007 Jan;28(1):19-21
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of all-trans retinoic acid combining chemotherapy and As4S4 in the maintenance treatment of patients with acute promyelocytic leukemia].
  • OBJECTIVE: To compare the efficacy of all-trans retinoic acid (ATRA) combining chemotherapy and As4S4 with ATRA combining chemotherapy for the maintenance treatment of patients with acute promyelocytic leukemia (APL).
  • METHODS: Sixty patients with APL induced to complete remission by ATRA and consolidated by chemotherapy were randomly divided into two groups.
  • The therapeutic effects, side effects and PML-RARalpha gene expression were analyzed.
  • Significant difference was also found in the positive rate of PML-RARalpha fusion gene between the two groups.
  • CONCLUSION: APL patients in maintenance therapy with ATRA + 6-MP + MTX + As4S4 can obtain a higher CCR.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Arsenicals / therapeutic use. Female. Humans. Male. Middle Aged. Remission Induction. Sulfides / therapeutic use. Treatment Outcome. Tretinoin / therapeutic use

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649720.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Sulfides; 0 / tetraarsenic tetrasulfide; 5688UTC01R / Tretinoin
  •  go-up   go-down


51. Tsai WH, Hsu HC, Lin CC, Ho CK, Kou YR: Role of interleukin-8 and growth-regulated oncogene-alpha in the chemotactic migration of all-trans retinoic acid-treated promyelocytic leukemic cells toward alveolar epithelial cells. Crit Care Med; 2007 Mar;35(3):879-85
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of interleukin-8 and growth-regulated oncogene-alpha in the chemotactic migration of all-trans retinoic acid-treated promyelocytic leukemic cells toward alveolar epithelial cells.
  • OBJECTIVE: Although all-trans retinoic acid (ATRA) can treat acute promyelocytic leukemia (APL), it also causes retinoic acid syndrome with presentations similar to acute respiratory distress syndrome.
  • We investigated the role of interleukin (IL)-8 and growth-regulated oncogene (GRO)-alpha in the chemotactic transmigration of ATRA-treated NB4 (ATRA-NB4) APL cells toward A549 alveolar epithelial cells.
  • CONCLUSIONS: IL-8 and GRO-alpha secreted from alveolar epithelial cells play an important role in the cell-cell interaction involved in the chemotactic transmigration of ATRA-treated APL cells toward alveolar epithelial cells.
  • [MeSH-major] Antineoplastic Agents / toxicity. Chemokines, CXC / physiology. Chemotaxis, Leukocyte / drug effects. Interleukin-8 / physiology. Leukemia, Promyelocytic, Acute / drug therapy. Pulmonary Alveoli / drug effects. Respiratory Distress Syndrome, Adult / chemically induced. Tretinoin / toxicity

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Crit Care Med. 2007 Mar;35(3):974-5 [17421102.001]
  • (PMID = 17235257.001).
  • [ISSN] 0090-3493
  • [Journal-full-title] Critical care medicine
  • [ISO-abbreviation] Crit. Care Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CXCL1 protein, human; 0 / Chemokine CXCL1; 0 / Chemokines, CXC; 0 / Interleukin-8; 5688UTC01R / Tretinoin
  •  go-up   go-down


52. Honig A, Engel JB, Segerer SE, Kranke P, Häusler S, Würfel W: Pregnancy-triggered antiphospholipid syndrome in a patient with multiple late miscarriages. Hum Reprod; 2010 Nov;25(11):2753-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antiphospholipid antibodies (APL), which had been negative before gestation, increased and remained high throughout pregnancy, thus suggesting a pregnancy-induced or -aggravated APS.
  • Thus, in order to diagnose and treat pregnancy-triggered APS in patients with unexplained recurrent miscarriage, screening for APL should also be performed at several time points after conception.
  • [MeSH-minor] Adult. Aspirin / therapeutic use. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Heparin, Low-Molecular-Weight / therapeutic use. Humans. Male. Pregnancy

  • Genetic Alliance. consumer health - Antiphospholipid Syndrome.
  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20823115.001).
  • [ISSN] 1460-2350
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Heparin, Low-Molecular-Weight; 143011-72-7 / Granulocyte Colony-Stimulating Factor; R16CO5Y76E / Aspirin
  •  go-up   go-down


53. Kantarjian H, O'Brien S, Cortes J, Wierda W, Faderl S, Garcia-Manero G, Issa JP, Estey E, Keating M, Freireich EJ: Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer; 2008 Oct 1;113(7 Suppl):1933-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.
  • Major therapeutic progress has been accomplished in leukemia and myelodysplastic syndrome (MDS) over the past 40 years, which may not be fully appreciated by the larger medical community.
  • The objective of this review was to briefly highlight the treatment breakthroughs in leukemia and MDS.
  • Therapeutic progress happened through better understanding of disease pathophysiologies and rational development of targeted agents, like imatinib mesylate in chronic myeloid leukemia (CML), and through astute, empirical discoveries in the clinic, like all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia (APL) and chlorodeoxyadenosine in hairy cell leukemia (HCL).
  • Today, the 5- to 10-year survival rates in patients with APL and HCL exceed 80%.
  • In patients with adult acute lymphocytic leukemia, modern intensive regimens have improved the 5-year survival rates from 20% up to 40%.
  • In patients with chronic lymphocytic leukemia, chemoimmunotherapy recently produced high rates of quality responses and improved long-term outcome.
  • In younger patients with acute myeloid leukemia (AML), the 5-year survival rates range from 40% to 50%, although elderly AML remains a therapeutic challenge.
  • Much therapeutic progress has been witnessed in leukemia and MDS, and much more is expected to occur soon.
  • [MeSH-major] Leukemia / therapy. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Myelodysplastic Syndromes / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Humans. Leukemia, Hairy Cell / mortality. Leukemia, Hairy Cell / therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy


54. Sultana TA, Abdul Mottalib M, Islam S, Khan MA, Choudhury S: Rt-PCR method for diagnosis and follow-up of hematological malignancies: first approach in Bangladesh. Bangladesh Med Res Counc Bull; 2008 Apr;34(1):1-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nested reverse-transcriptase polymerase chain reaction (rt-PCR) was performed on 58 leukemia patients at BIRDEM Laboratory, as a pioneering work in Bangladesh.
  • Thirty of themwere examined for the presence of BCR-ABL being clinically and morphologically diagnosed as chronic myeloid leukemia (CML) and 28 for PML-RARalpha fusion transcripts being clinically and morphologically diagnosed as acute promyelocytic leukemia (APL/ AML M3).
  • The cases were selected for targeted therapy with imatinib mesylate and all-Trans retinoic acid (ATRA) to treat CML and APL respectively.
  • Positive results for PML-RARalpha were found for 12 out of 14 (85.70%) untreated cases and 11 out of 16 (68.75%) treated cases.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Leukemia, Promyelocytic, Acute / diagnosis. Reverse Transcriptase Polymerase Chain Reaction / methods
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Bangladesh. Benzamides. Child. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Piperazines / therapeutic use. Prospective Studies. Pyrimidines / therapeutic use. Treatment Outcome. Tretinoin / therapeutic use

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18783070.001).
  • [ISSN] 0377-9238
  • [Journal-full-title] Bangladesh Medical Research Council bulletin
  • [ISO-abbreviation] Bangladesh Med Res Counc Bull
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bangladesh
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 5688UTC01R / Tretinoin; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


55. Tebo AE, Jaskowski TD, Phansalkar AR, Litwin CM, Branch DW, Hill HR: Diagnostic performance of phospholipid-specific assays for the evaluation of antiphospholipid syndrome. Am J Clin Pathol; 2008 Jun;129(6):870-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnostic performance of commercially available nonstandard antiphospholipid (aPL) assays for the evaluation of antiphospholipid syndrome (APS) is unknown.
  • Overall, the combined sensitivity of the aPL assays differed significantly between manufacturers and did not improve the diagnostic yield for APS.
  • [MeSH-minor] Adult. Area Under Curve. Biomarkers / blood. Cross-Sectional Studies. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunoglobulin G / immunology. Immunoglobulin M / immunology. Male. Phosphatidic Acids / immunology. Phosphatidylcholines / immunology. Phosphatidylethanolamines / immunology. Phosphatidylglycerols / immunology. Phosphatidylinositols / immunology. Phosphatidylserines / immunology. Predictive Value of Tests

  • Genetic Alliance. consumer health - Antiphospholipid Syndrome.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18480002.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Biomarkers; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Phosphatidic Acids; 0 / Phosphatidylcholines; 0 / Phosphatidylethanolamines; 0 / Phosphatidylglycerols; 0 / Phosphatidylinositols; 0 / Phosphatidylserines; 0 / Phospholipids; 39382-08-6 / phosphatidylethanolamine
  •  go-up   go-down


56. Sidelmann JJ, Sjøland JA, Gram J, Bertelsen V, Mourits-Andersen T, Münster H, Münster AM, Jespersen J: Lupus anticoagulant is significantly associated with inflammatory reactions in patients with suspected deep vein thrombosis. Scand J Clin Lab Invest; 2007;67(3):270-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Lupus anticoagulant (LA) and antiphospholipid antibodies (aPL) are suggested as risk factors for development of deep vein thrombosis (DVT) among patients without systemic lupus erythematosus (SLE).
  • In this study the associations between aPL, LA and inflammation were investigated in 170 consecutive patients without SLE, but with a tentative diagnosis of DVT.
  • CONCLUSIONS: The present study supports a strong association between inflammatory reactions and development of LA in patients with suspected DVT, whereas no significant association was demonstrated between LA or aPL and DVT.
  • [MeSH-minor] Adult. Aged. Antibodies, Anticardiolipin / blood. Antibodies, Anticardiolipin / immunology. Biomarkers. Blood Coagulation Tests. C-Reactive Protein / analysis. C-Reactive Protein / immunology. Female. Humans. Male. Middle Aged. Phlebography. Risk Factors

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454841.001).
  • [ISSN] 0036-5513
  • [Journal-full-title] Scandinavian journal of clinical and laboratory investigation
  • [ISO-abbreviation] Scand. J. Clin. Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antibodies, Anticardiolipin; 0 / Biomarkers; 0 / Lupus Coagulation Inhibitor; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


57. Kaito K, Katayama T, Masuoka H, Nishiwaki K, Sano K, Sekiguchi N, Hagino T, Kobayashi M: CD2+ acute promyelocytic leukemia is associated with leukocytosis, variant morphology and poorer prognosis. Clin Lab Haematol; 2005 Oct;27(5):307-11
Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD2+ acute promyelocytic leukemia is associated with leukocytosis, variant morphology and poorer prognosis.
  • The T cell-lineage marker CD2 is sometimes expressed in acute promyelocytic leukemia (APL), and CD2 expression is reported to correlate with some clinical characteristics.
  • However, the significance of CD2 expression in APL has not been fully elucidated.
  • We evaluated CD2 expression in APL treated by the same treatment strategy in a single institute, and whether it had any special characteristics.
  • Among 29 APL, 6 were positive for CD2.
  • Patients with CD2+ APL tended to have a higher leukocyte count than CD2- APL (34.5 +/- 13.1/l vs. 6.8 +/- 2.1/l), morphological characteristics as variant-APL (50 vs. 0%).
  • The CR rate of CD2- APL was 87.0% while that of CD2+ APL was 50 %.
  • The mortality was 13.0 and 66.7%, respectively, and the survival rate was significantly lower in CD2+ APL.
  • CD2 expression was proven to be a risk factor associated with death in addition to the morphological characteristics of variant-APL and leukocytosis.
  • These results indicated that CD2 expression might have a significant impact on the prognosis of APL.
  • Whether CD2+ APL should be characterized as a special clinical entity should be discussed in a larger patient population.
  • [MeSH-major] Antigens, CD2 / analysis. Leukemia, Promyelocytic, Acute / pathology
  • [MeSH-minor] Adult. Antigens, Neoplasm / analysis. Cell Shape. Humans. Immunophenotyping. Leukocyte Count. Leukocytosis / etiology. Middle Aged. Prognosis. Remission Induction. Risk Factors. Survival Analysis. T-Lymphocytes

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16178910.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD2; 0 / Antigens, Neoplasm
  •  go-up   go-down


58. Lin WS, Chen PC, Yang CD, Cho E, Hahn BH, Grossman J, Hwang KK, Chen PP: Some antiphospholipid antibodies recognize conformational epitopes shared by beta2-glycoprotein I and the homologous catalytic domains of several serine proteases. Arthritis Rheum; 2007 May;56(5):1638-47
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To test the hypothesis that some antiphospholipid antibodies (aPL) in patients with the antiphospholipid syndrome (APS) recognize a conformational epitope shared by beta2-glycoprotein I (beta2GPI; the major autoantigen for the antiphospholipid antibodies) and the homologous catalytic domains of several serine proteases (such as thrombin, activated protein C [APC], and plasmin) involved in hemostasis.
  • METHODS: We generated 4 new IgG monoclonal aPL (2 screened against beta2GPI, 1 against thrombin, and 1 against protein C) from 2 APS patients.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol Methods. 1986 May 1;89(1):61-72 [3084658.001]
  • [Cites] J Immunol Methods. 1985 Mar 18;77(2):305-19 [3981007.001]
  • [Cites] N Engl J Med. 1997 Jul 17;337(3):154-60 [9219701.001]
  • [Cites] Lancet. 1997 Nov 22;350(9090):1491-3 [9388393.001]
  • [Cites] Science. 1998 Sep 11;281(5383):1662-5 [9733510.001]
  • [Cites] J Med Chem. 1999 Apr 22;42(8):1376-83 [10212123.001]
  • [Cites] Br J Haematol. 1999 Apr;105(1):102-9 [10233371.001]
  • [Cites] Arthritis Rheum. 1999 Jul;42(7):1309-11 [10403256.001]
  • [Cites] J Immunol. 1999 Oct 15;163(8):4604-11 [10510405.001]
  • [Cites] Arthritis Rheum. 1999 Oct;42(10):2132-8 [10524684.001]
  • [Cites] J Thromb Haemost. 2005 Jul;3(7):1385-91 [15978096.001]
  • [Cites] Ann N Y Acad Sci. 2005 Jun;1050:250-6 [16014540.001]
  • [Cites] Arthritis Rheum. 2005 Dec;52(12):4018-27 [16320350.001]
  • [Cites] J Thromb Haemost. 2006 Feb;4(2):295-306 [16420554.001]
  • [Cites] J Autoimmun. 2006 Feb;26(1):57-65 [16330187.001]
  • [Cites] Blood. 1988 Aug;72(2):512-9 [2456797.001]
  • [Cites] J Biol Chem. 1989 Jan 5;264(1):616-24 [2521222.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jun;87(11):4120-4 [2349221.001]
  • [Cites] Lancet. 1990 Jul 21;336(8708):177-8 [1973491.001]
  • [Cites] Thromb Haemost. 1991 Dec 2;66(6):629-32 [1796407.001]
  • [Cites] Blood. 1993 May 15;81(10):2618-25 [8166780.001]
  • [Cites] Blood. 1994 May 15;83(10):2878-92 [8180383.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Jul 15;202(1):367-73 [8037734.001]
  • [Cites] Thromb Haemost. 1994 May;71(5):670-4 [8091396.001]
  • [Cites] Springer Semin Immunopathol. 1994;16(2-3):223-45 [7716706.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8606-11 [8710918.001]
  • [Cites] J Immunol. 1996 Dec 15;157(12):5732-8 [8955227.001]
  • [Cites] Arthritis Rheum. 2000 Feb;43(2):440-3 [10693886.001]
  • [Cites] Br J Haematol. 2000 Mar;108(4):871-5 [10792298.001]
  • [Cites] Thromb Haemost. 2000 Sep;84(3):388-95 [11019960.001]
  • [Cites] J Immunol. 2001 Dec 15;167(12):7192-8 [11739542.001]
  • [Cites] N Engl J Med. 2002 Mar 7;346(10):752-63 [11882732.001]
  • [Cites] Lupus. 2002;11(4):215-20 [12043884.001]
  • [Cites] Arthritis Rheum. 2003 Jun;48(6):1622-30 [12794830.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1193-200 [12937161.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2121-6 [14630788.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5765-73 [15100323.001]
  • [Cites] Clin Exp Immunol. 2004 Jun;136(3):393-401 [15147339.001]
  • [Cites] Pathology. 2004 Apr;36(2):129-38 [15203748.001]
  • [Cites] Curr Opin Hematol. 2004 May;11(3):165-9 [15257015.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2783-90 [15242878.001]
  • [Cites] Nature. 1983 Jan 20;301(5897):214-21 [6337343.001]
  • [Cites] EMBO J. 1996 Dec 16;15(24):6822-31 [9003757.001]
  • (PMID = 17469158.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / AR042506-10; United States / NIAMS NIH HHS / AR / R01 AR042506; United States / NIAMS NIH HHS / AR / AR-42506; United States / NIAMS NIH HHS / AR / R01 AR042506-10
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Anticardiolipin; 0 / Antibodies, Antiphospholipid; 0 / Antibodies, Monoclonal; 0 / Blood Coagulation Factors; 0 / Epitopes; 0 / Immunoglobulin G; 0 / Receptors, Cell Surface; 0 / activated protein C receptor; 0 / beta 2-Glycoprotein I; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.5 / Thrombin; EC 3.4.21.7 / Fibrinolysin
  • [Other-IDs] NLM/ NIHMS25118; NLM/ PMC1950582
  •  go-up   go-down


59. Martinuc Porobic J, Avcin T, Bozic B, Kuhar M, Cucnik S, Zupancic M, Prosenc K, Kveder T, Rozman B: Anti-phospholipid antibodies following vaccination with recombinant hepatitis B vaccine. Clin Exp Immunol; 2005 Nov;142(2):377-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were no sex-dependent differences in tested antibodies observed and no associations between levels of aPL and levels of anti-HBV antibodies.
  • We conclude that HBV can induce aPL, although rarely.
  • [MeSH-minor] Adult. Antibodies, Anticardiolipin / biosynthesis. Autoimmunity. Female. Glycoproteins / immunology. Humans. Immunization Schedule. Immunoglobulin G / biosynthesis. Immunoglobulin M / biosynthesis. Lupus Coagulation Inhibitor / biosynthesis. Male. Vaccination. beta 2-Glycoprotein I

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rheumatology (Oxford). 1999 Oct;38(10):978-83 [10534549.001]
  • [Cites] Adv Vet Med. 1999;41:733-47 [9890057.001]
  • [Cites] J Autoimmun. 2000 Feb;14(1):11-3 [10648111.001]
  • [Cites] Hepatology. 2000 Feb;31(2):521-7 [10655280.001]
  • [Cites] Clin Diagn Lab Immunol. 2000 Mar;7(2):241-4 [10702499.001]
  • [Cites] J Gastroenterol. 2000;35(4):272-7 [10777156.001]
  • [Cites] Ann Rheum Dis. 2000 Jun;59(6):483-6 [10834867.001]
  • [Cites] Clin Chem Lab Med. 2000 Aug;38(8):777-83 [11071073.001]
  • [Cites] Arthritis Rheum. 2002 Feb;46(2):545-52 [11840458.001]
  • [Cites] Clin Exp Rheumatol. 2002 Jan-Feb;20(1):101-8 [11892692.001]
  • [Cites] J Clin Invest. 2002 Mar;109(6):797-804 [11901188.001]
  • [Cites] J Investig Allergol Clin Immunol. 2002;12(3):155-68 [12530114.001]
  • [Cites] Expert Opin Drug Saf. 2003 Mar;2(2):113-22 [12904111.001]
  • [Cites] Clin Immunol. 2004 Aug;112(2):190-9 [15240163.001]
  • [Cites] Ann Rheum Dis. 2004 Oct;63(10):1312-7 [15361392.001]
  • [Cites] Thromb Res. 1991 Aug 15;63(4):433-43 [1754996.001]
  • [Cites] Am J Pathol. 1997 Jun;150(6):2197-207 [9176409.001]
  • [Cites] J Autoimmun. 2000 Feb;14(1):1-10 [10648110.001]
  • (PMID = 16232227.001).
  • [ISSN] 0009-9104
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Anticardiolipin; 0 / Antibodies, Antiphospholipid; 0 / Engerix-B; 0 / Glycoproteins; 0 / Hepatitis B Vaccines; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Lupus Coagulation Inhibitor; 0 / Vaccines, Synthetic; 0 / beta 2-Glycoprotein I
  • [Other-IDs] NLM/ PMC1809502
  •  go-up   go-down


60. Naclerio C, D'Angelo S, Baldi S, Tagliamonte G, Scarpato S: Efficacy of bosentan in the treatment of a patient with mixed connective tissue disease complicated by pulmonary arterial hypertension. Clin Rheumatol; 2010 Jun;29(6):687-90
MedlinePlus Health Information. consumer health - Pulmonary Hypertension.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indeed, the patient in this study very likely improved secondary to the effect of bosentan which produces systemic and pulmonary vasodilatation associated with pulmonary vascular remodeling as well as possible antifibrotic, anti-inflammatory and antiatherothrombotic effects on cells of lungs damaged by an aPL-antibody mediated mechanism.
  • [MeSH-minor] Adult. Antihypertensive Agents / therapeutic use. Echocardiography. Female. Humans. Treatment Outcome


61. Kawakami T, Yamazaki M, Mizoguchi M, Soma Y: High titer of anti-phosphatidylserine-prothrombin complex antibodies in patients with cutaneous polyarteritis nodosa. Arthritis Rheum; 2007 Dec 15;57(8):1507-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the possible role of antiphospholipid antibodies (aPL) in CPN, we measured serum lupus anticoagulant (LAC), IgG and IgM anticardiolipin (aCL) and anti-phosphatidylserine-prothrombin complex (anti-PS/PT) antibodies, and anti-beta(2)-glycoprotein I-dependent cardiolipin (anti-beta(2)GPI/CL) antibodies in the 16 CPN patients, 8 microscopic polyangiitis (MPA) patients, 33 systemic lupus erythematosus (SLE) patients, and 23 healthy controls.
  • No MPA patients had aPL.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Anticardiolipin / blood. Biomarkers / blood. Case-Control Studies. Female. Humans. Immunoglobulin G / blood. Immunoglobulin M / blood. Lupus Coagulation Inhibitor / blood. Male. Middle Aged. Vasculitis / blood. Vasculitis / immunology

  • Genetic Alliance. consumer health - Cutaneous Polyarteritis Nodosa.
  • Genetic Alliance. consumer health - Polyarteritis nodosa.
  • Genetic Alliance. consumer health - Prothrombin.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18050170.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Antibodies, Anticardiolipin; 0 / Antibodies, Antiphospholipid; 0 / Biomarkers; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Lupus Coagulation Inhibitor; 0 / Phosphatidylserines; 9001-26-7 / Prothrombin
  •  go-up   go-down


62. Tang H, Li ZK, Lin J, Huang X, Gan CF, Li RH, Hu W, Fang DZ: [Effects of a high-carbohydrate, low-fat diet on the levels of serum phospholipids and triglycerides]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Sep;38(5):822-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Correlation analyses indicated that after HC/LF diet the change of serum PL (APL) had a negative correlation with the change of BMI(deltaBMI),a positive correlation with the change of HDL-TG(deltaHDL-TG) and insulin (delta insulin).
  • [MeSH-minor] Adult. Anthropometry. Female. Humans. Insulin / blood. Lipoproteins, HDL / blood. Male. Young Adult

  • MedlinePlus Health Information. consumer health - Carbohydrates.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17953368.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Dietary Carbohydrates; 0 / Insulin; 0 / Lipoproteins, HDL; 0 / Phospholipids; 0 / Triglycerides
  •  go-up   go-down


63. Huang HH, Zhu JY, Zhong JH, Wang HR, Zhong H, Han JY, Chen FY: [Correlation between expression of apoptosis-related gene pnas-2 and leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug;15(4):738-42
Hazardous Substances Data Bank. ARSENIC TRISULFIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation between expression of apoptosis-related gene pnas-2 and leukemia].
  • The study was purposed to explore the correlation between apoptosis-related gene pnas-2 and leukemia.
  • The RT-PCR was performed to detect the expression levels of pnas-2 gene in NB4, K562, U937 cells before and after treatment with AS(4)S(4), and to analysis the expression change of pnas-2 gene in bone marrow cells from patients with acute leukemia before and after chemotherapy.
  • The positive expression rate of pnas-2 in cells from untreated patients with acute leukemia was 100%, and was significantly higher than that in normal control group.
  • It is concluded that the pnas-2 gene may be closely related with apotosis of arsenic sulfide treated APL cells, and may consider as a molecular biological remission marker in acute leukemia.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17708794.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Arsenicals; 0 / PNAS-2 protein, human; 0 / Sulfides; 44SIJ800OX / arsenic trisulfide
  •  go-up   go-down


64. Sastre A, Gago E, Baños M, Gómez E: [Acute renal failure in the transretinoic syndrome]. Nefrologia; 2007;27(2):184-90
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute renal failure in the transretinoic syndrome].
  • The all-trans retinoic acid (ATRA) is the treatment of first line of acute promyelocytic leukemia (APL).
  • MATERIAL AND METHODS: We studied to the 29 patients diagnosed in (January of 2002 - December of 2004) of acute promyelocytic leukemia (APL), which were treated with ATRA, all received the 45 dose of mg/m(2)/d .
  • The diagnosis of the leukemia was made by citomorphologist analysis.
  • The acute renal failure appeared in 10 of the 14 patients with SAR (71.4%), to 12+/-5 (1-25) days of the beginning of the treatment and their duration it was of 14+/-5 (1-46) days.
  • CONCLUSIONS: The appearance of acute renal failure in the course of the SAR is frequent, being observed deterioration of the renal function that needs substitute renal treatment in more than half the cases.
  • [MeSH-major] Acute Kidney Injury / chemically induced. Antineoplastic Agents / adverse effects. Tretinoin / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Male. Middle Aged. Prevalence. Syndrome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17564563.001).
  • [ISSN] 0211-6995
  • [Journal-full-title] Nefrología : publicación oficial de la Sociedad Española Nefrologia
  • [ISO-abbreviation] Nefrologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


65. Plesner AM, Jarløv JO: [Infection control and hygiene in daycare institutions, schools and nursing homes]. Ugeskr Laeger; 2007 Nov 26;169(48):4172-4
MedlinePlus Health Information. consumer health - Infection Control.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adolescent. Adult. Child. Child Day Care Centers. Child, Preschool. Counseling. Denmark. Humans. Infant. Methicillin Resistance. Nursing Homes. Physician's Role. Professional Competence. Schools

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18211786.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


66. Betancourt-García RD, Castro J, Fernández AC, López-Enríquez A, Fradera J, Pacheco E: Acquired acute myelogenous leukemia after therapy for acute promyelocytic leukemia with t(15;17): a case report and review of the literature. P R Health Sci J; 2009 Jun;28(2):146-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired acute myelogenous leukemia after therapy for acute promyelocytic leukemia with t(15;17): a case report and review of the literature.
  • Therapy-related myelodysplastic syndrome (t-MDS) and therapy-related acute myelogenous leukemia (t-AML) in patients with acute promyelocytic leukemia (APL) are rare events.
  • The cumulative exposure to chemotherapy with alkylating agents and topoisomerase II inhibitors is associated with t-AML that may develop any time after the completion of the treatment.
  • We report the case of an acquired AML who previously received therapy for APL, after two years of being diagnosed.
  • To our knowledge this is the first documented case in Puerto Rico of a patient with APL that developed a t-AML without the characteristic chromosomal and morphologic findings of APL.
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Leukemia, Promyelocytic, Acute / drug therapy. Neoplasms, Second Primary / etiology. Translocation, Genetic
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adult. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosomes, Human, Pair 15 / ultrastructure. Chromosomes, Human, Pair 17 / ultrastructure. Chromosomes, Human, Pair 21 / ultrastructure. Chromosomes, Human, Pair 3 / ultrastructure. Chromosomes, Human, Pair 7. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Daunorubicin / adverse effects. Drug Synergism. Fatal Outcome. Humans. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Monosomy. Tretinoin / administration & dosage


67. Zhou J, Hu LH, Cui Z, Wang GF, Li JM, Zhao YH, Fan SJ, Li LM, Cao FL, Han XY: [In vitro stimulation of retinoic acid syndrome by rotary cell culture system and its relationship with expression of CXCR4 and SDF-1 alpha]. Zhonghua Xue Ye Xue Za Zhi; 2007 Dec;28(12):799-803
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: SDF-1 alpha mRNA from healthy adult lung tissue was measured by RT-PCR, CXCR4 protein expression on the cell membrane of APL cells induced by ATRA (APL-ATRA) was tested by FCM, and the rotary cell culture system (RCCS) was used to build a modal for in vitro stimulation of APL-ATRA infiltrating human lung tissue.
  • The ability of APL-ATRA in adhesion, migration and infiltration was observed by interference from DEX, Ara-C and DNR.
  • RESULTS: The APL-ATRA cells could evidently infiltrate into normal lung tissue.
  • Mean fluorescence intensity (MFI) of CXCR4 on the cell membrane of APL-ATRA cells was 30.6 +/- 1.8, which was much higher than that on unspecialized APL cells (9.8 +/- 4.2).
  • Contrary to the control groups, DEX could dramatically restrain the ability of APL-ATRA cells in adhesion and migration [(27.2 +/- 2.6)% vs. (46.0 +/- 3.0)%, (28.1 +/- 4.0)% vs. (48.2 +/- 3.0)%], while Ara-C and DNR could distinctly depress the ability in adhesion, migration and infiltration [(28.1 +/- 3.0)%, (30.2 +/- 3.2)% vs. (46.0 +/- 3.0)%; (29.0 +/- 4.0)%, (23.0 +/- 5.2)% vs. (48.2 +/- 3.0)%; (16.8 +/- 7.6)%, (17.1 +/- 6.0)% vs. (43.6 +/- 5.0)%].
  • CONCLUSION: In vitro APL-ATRA cells can infiltrate into the human lung tissue.
  • High expression of CXCR4 on APL-ATRA and SDF-1 alpha in the lung tissue may be one of the molecular mechanisms of the lung infiltration and RAS.
  • DEX, Ara-C and DNR can dramatically restrain the ability of APL-ATRA cells in adhesion, migration and infiltration.
  • [MeSH-major] Chemokine CXCL12 / metabolism. Leukemia, Promyelocytic, Acute / metabolism. Receptors, CXCR4 / metabolism. Tretinoin / adverse effects
  • [MeSH-minor] Adolescent. Adult. Cell Adhesion. Cell Culture Techniques. Cell Movement. Child. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18476589.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Chemokine CXCL12; 0 / Receptors, CXCR4; 5688UTC01R / Tretinoin
  •  go-up   go-down


68. Sokol DK, O'Brien RS, Wagenknecht DR, Rao T, McIntyre JA: Antiphospholipid antibodies in blood and cerebrospinal fluids of patients with psychosis. J Neuroimmunol; 2007 Oct;190(1-2):151-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antiphospholipid antibodies (aPL) have been reported in the cerebrospinal fluids (CSF) of neurology patients but no CSF studies with psychiatric patients exist.
  • We tested serum from 100 hospitalized psychotic patients having hallucinations and/or delusions for aPL.
  • Patients with positive serum aPL findings were asked to submit CSF for aPL testing.
  • Five CSF samples had aPL specificities not found in the patient's serum suggesting the possibility of intrathecal synthesis.
  • Specificity and isotype discordance between CSF and blood aPL in these psychiatric patients implicates a central nervous system independent autoimmune process that may have an underlying association with the pathophysiology of their diseases.
  • [MeSH-minor] Adolescent. Adult. Aged. Autoimmune Diseases of the Nervous System / blood. Autoimmune Diseases of the Nervous System / cerebrospinal fluid. Autoimmune Diseases of the Nervous System / immunology. Bipolar Disorder / blood. Bipolar Disorder / cerebrospinal fluid. Bipolar Disorder / immunology. Female. Hallucinations / blood. Hallucinations / cerebrospinal fluid. Hallucinations / immunology. Humans. Lipid Metabolism / immunology. Male. Middle Aged. Predictive Value of Tests. Schizophrenia / blood. Schizophrenia / cerebrospinal fluid. Schizophrenia, Paranoid / blood. Schizophrenia, Paranoid / cerebrospinal fluid. Schizophrenia, Paranoid / immunology. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Psychotic Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868908.001).
  • [ISSN] 0165-5728
  • [Journal-full-title] Journal of neuroimmunology
  • [ISO-abbreviation] J. Neuroimmunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Phospholipids
  •  go-up   go-down


69. Tarr T, Lakos G, Bhattoa HP, Shoenfeld Y, Szegedi G, Kiss E: Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus; 2007;16(1):39-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 272 lupus patients were followed up for five years during which the presence of aPL antibodies [anticardiolipin (aCL), anti-beta2-glycoprotein I (abeta2GPI) and lupus anticoagulant (LAC)] were determined, and all thrombotic incidents and antithrombotic therapy-related data were collected.
  • At baseline, three groups were constituted, an aPL- group with 107 aPL negative patients, an aPL+ group with 81 aPL positive patients without clinical thrombosis and a secondary antiphospholipid syndrome (APS) group with 84 aPL+ patients who met the Sapporo criteria.
  • LAC was more common in the APS than the aPL+ group (32.1% versus 9.9%, P < 0.001).
  • The prevalence of clinical thrombotic events was significantly higher when all three types of aPL were present compared to only aCL positive cases.
  • During follow up, aPL appeared in 7.5% of the aPL- group, and 2.8% of this group had thrombotic complications.
  • In the aPL+ group, thrombotic events reoccurred in 1.9% of those receiving antithrombotic prophylaxis and 6.9% of those without primary prophylaxis.
  • These findings indicate that LAC, constant and cumulative presence of aPL and previous thrombosis are positive predictors for the development of thrombotic complication in lupus patients.
  • [MeSH-minor] Adult. Antibodies, Anticardiolipin / blood. Antibodies, Anticardiolipin / immunology. Antibody Specificity. Anticoagulants / adverse effects. Anticoagulants / therapeutic use. Autoantigens / immunology. Female. Fibrinolytic Agents / adverse effects. Fibrinolytic Agents / therapeutic use. Follow-Up Studies. Humans. Lupus Coagulation Inhibitor / blood. Male. Middle Aged. Platelet Aggregation Inhibitors / adverse effects. Platelet Aggregation Inhibitors / therapeutic use. Risk Factors. Stroke / epidemiology. Stroke / etiology. Stroke / prevention & control. beta 2-Glycoprotein I / immunology

  • Genetic Alliance. consumer health - Lupus.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Lupus.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17283584.001).
  • [ISSN] 0961-2033
  • [Journal-full-title] Lupus
  • [ISO-abbreviation] Lupus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Anticardiolipin; 0 / Antibodies, Antiphospholipid; 0 / Anticoagulants; 0 / Autoantigens; 0 / Fibrinolytic Agents; 0 / Lupus Coagulation Inhibitor; 0 / Platelet Aggregation Inhibitors; 0 / beta 2-Glycoprotein I
  •  go-up   go-down


70. Tincani A, Rebaioli CB, Andreoli L, Lojacono A, Motta M: Neonatal effects of maternal antiphospholipid syndrome. Curr Rheumatol Rep; 2009 Feb;11(1):70-6
MedlinePlus Health Information. consumer health - Uncommon Infant and Newborn Problems.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antiphospholipid antibodies (aPL) can impair the physiologic development of a fetus during pregnancy not only by causing thrombosis of the placental vessels, but also by directly binding throphoblast cells and modifying their functions.
  • Consequently, the presence of aPL in pregnant women is linked to an increased rate of pregnancy complications.
  • The close association between aPL and obstetric pathology supports the inclusion of these manifestations in the clinical classification criteria of antiphospholipid syndrome.
  • About 30% of children born to mothers with aPL passively acquire these autoantibodies; fortunately, the occurrence of thrombosis seems extremely rare in these babies.
  • The prospective ongoing studies of children born to antiphospholipid syndrome patients reassure us about their general good health; however, some data suggest that learning difficulties might occur, possibly related to in utero exposure to aPL.
  • [MeSH-minor] Adult. Animals. Female. Follow-Up Studies. Humans. Infant, Newborn. Learning Disorders / etiology. Learning Disorders / immunology. Learning Disorders / psychology. Maternal-Fetal Exchange. Mice. Pre-Eclampsia. Pregnancy. Young Adult

  • Genetic Alliance. consumer health - Antiphospholipid Syndrome.
  • MedlinePlus Health Information. consumer health - Common Infant and Newborn Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Obstet Gynecol Scand. 2004 Sep;83(9):808-17 [15315591.001]
  • [Cites] Lupus. 2002;11(1):4-10 [11898917.001]
  • [Cites] Br J Obstet Gynaecol. 1987 Jun;94(6):604-5 [3620409.001]
  • [Cites] Curr Rheumatol Rep. 2007 Jun;9(3):219-25 [17531175.001]
  • [Cites] Obstet Gynecol. 1992 Sep;80(3 Pt 1):365-8 [1379703.001]
  • [Cites] Hum Reprod. 2000 May;15(5):1170-2 [10783372.001]
  • [Cites] J Autoimmun. 2007 Mar-May;28(2-3):160-4 [17419007.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2319-24 [17283337.001]
  • [Cites] Pediatr Neurol. 2002 Jan;26(1):68-70 [11814740.001]
  • [Cites] Lupus. 2002;11(10):649 [12413058.001]
  • [Cites] Lupus. 1993 Aug;2(4):233-7 [8268971.001]
  • [Cites] Clin Rev Allergy Immunol. 2008 Jun;34(3):332-7 [18175073.001]
  • [Cites] J Perinat Med. 1997;25(2):192-6 [9189840.001]
  • [Cites] J Perinat Med. 1999;27(3):183-7 [10503179.001]
  • [Cites] Lupus. 2004;13(10):805-11 [15540514.001]
  • [Cites] Lupus. 2007;16(8):634-41 [17711900.001]
  • [Cites] Arthritis Rheum. 2008 Mar 15;59(3):345-51 [18311760.001]
  • [Cites] Lupus. 2003;12(6):436-42 [12873044.001]
  • [Cites] Biol Neonate. 2004;86(4):230-4 [15256800.001]
  • [Cites] Curr Rheumatol Rep. 2008 Jan;10(1):67-73 [18457615.001]
  • [Cites] Autoimmun Rev. 2006 Dec;6(2):76-80 [17138247.001]
  • [Cites] J Int Neuropsychol Soc. 1997 Jul;3(4):370-6 [9260446.001]
  • [Cites] Clin Exp Immunol. 2005 Nov;142(2):377-80 [16232227.001]
  • [Cites] Lupus. 2004;13(9):713-7 [15485110.001]
  • [Cites] Clin Immunol. 2004 Aug;112(2):190-9 [15240163.001]
  • [Cites] Clin Rheumatol. 2008 Jan;27(1):1-4 [17912576.001]
  • [Cites] Clin Exp Rheumatol. 1996 Mar-Apr;14(2):131-6 [8737718.001]
  • [Cites] N Engl J Med. 1992 Apr 2;326(14):952; author reply 953-4 [1542348.001]
  • [Cites] Ann Rheum Dis. 2005 Feb;64(2):273-8 [15647435.001]
  • [Cites] J Exp Med. 2002 Jan 21;195(2):211-20 [11805148.001]
  • [Cites] Rheumatol Int. 2007 Dec;28(2):171-4 [17576561.001]
  • [Cites] J Thromb Haemost. 2006 Feb;4(2):295-306 [16420554.001]
  • [Cites] Am J Perinatol. 2006 May;23(4):247-51 [16625500.001]
  • [Cites] J Rheumatol. 1997 Sep;24(9):1725-33 [9292795.001]
  • [Cites] Semin Thromb Hemost. 2008 Apr;34(3):267-73 [18720306.001]
  • [Cites] Pediatr Dermatol. 2003 Jan-Feb;20(1):60-7 [12558850.001]
  • [Cites] Lancet. 1983 Jun 18;1(8338):1361-3 [6134138.001]
  • [Cites] J Clin Invest. 2003 Dec;112(11):1644-54 [14660741.001]
  • [Cites] Lancet. 1983 Nov 26;2(8361):1211-4 [6139567.001]
  • [Cites] Obstet Gynecol. 1996 Apr;87(4):489-93 [8602296.001]
  • [Cites] Autoimmunity. 2003 Feb;36(1):27-32 [12765468.001]
  • [Cites] Clin Exp Rheumatol. 1998 Sep-Oct;16(5):605-10 [9779312.001]
  • [Cites] Ann N Y Acad Sci. 2002 Jun;966:415-24 [12114299.001]
  • [Cites] Arch Pediatr Adolesc Med. 2003 Apr;157(4):397-402 [12695238.001]
  • [Cites] Am J Obstet Gynecol. 2007 Feb;196(2):167.e1-5 [17306667.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1997 May;73(1):37-42 [9175687.001]
  • [Cites] Arthritis Rheum. 1999 Jul;42(7):1309-11 [10403256.001]
  • [Cites] Lupus. 2004;13(9):649-52 [15485095.001]
  • (PMID = 19171114.001).
  • [ISSN] 1534-6307
  • [Journal-full-title] Current rheumatology reports
  • [ISO-abbreviation] Curr Rheumatol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


71. Kusakabe M, Suzukawa K, Nanmoku T, Obara N, Okoshi Y, Mukai HY, Hasegawa Y, Kojima H, Kawakami Y, Ninomiya H, Nagasawa T: Detection of the STAT5B-RARA fusion transcript in acute promyelocytic leukemia with the normal chromosome 17 on G-banding. Eur J Haematol; 2008 May;80(5):444-7
Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of the STAT5B-RARA fusion transcript in acute promyelocytic leukemia with the normal chromosome 17 on G-banding.
  • Acute promyelocytic leukemia (APL) is characterized by chromosomal rearrangements of 17q21, leading to fusion of the gene-encoding retinoic acid receptor alpha (RARA) with a number of alternative partner genes.
  • We report a rare case of APL with STAT5B-RARA fusion transcript and the normal chromosome 17 on G-banding.
  • Administration of all trans-retinoic acid improved disseminated intravascular coagulation without decrease of the leukemia cells in his peripheral blood and bone marrow.
  • The molecular mechanism of fusion between STAT5B and RARA by chromosomal rearrangement is discussed based on the data from genome database.
  • Clinical characteristics of APL with STAT5B-RARA are also discussed.
  • [MeSH-major] Chromosomes, Human, Pair 17 / genetics. Leukemia, Promyelocytic, Acute / genetics. Oncogene Proteins, Fusion / analysis. Oncogene Proteins, Fusion / genetics. STAT5 Transcription Factor / analysis. STAT5 Transcription Factor / genetics. Transcription, Genetic / genetics
  • [MeSH-minor] Adult. Aged. Amino Acid Sequence. Base Sequence. Humans. Karyotyping. Male. Middle Aged. Molecular Sequence Data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Haematol. 2009 Nov;83(5):499-501 [19624718.001]
  • (PMID = 18221386.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / STAT5 Transcription Factor; 0 / STAT5-RARalpha protein, human
  •  go-up   go-down


72. Lin TL, Vala MS, Barber JP, Karp JE, Smith BD, Matsui W, Jones RJ: Induction of acute lymphocytic leukemia differentiation by maintenance therapy. Leukemia; 2007 Sep;21(9):1915-20
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of acute lymphocytic leukemia differentiation by maintenance therapy.
  • Despite extensive study in many malignancies, maintenance therapy has clinically benefited only two diseases: acute lymphocytic leukemia (ALL) and acute promyelocytic leukemia (APL).
  • ALL maintenance therapy utilizes low-dose 6-mercaptopurine (6MP) and methotrexate (MTX), while maintenance in APL primarily consists of all-trans-retinoic acid (ATRA).
  • 6MP and MTX as used in ALL are also now usually added to maintenance ATRA for APL, based on data suggesting an improved disease-free survival.
  • Thus, we studied whether maintenance therapy in ALL, like ATRA in APL, may be inducing terminal differentiation of ALL progenitors.
  • The APL cell line NB4, the ALL cell lines REH and RS4;11, and patients' ALL blasts were incubated with ATRA, 6MP, and MTX in vitro.
  • All three drugs inhibited the clonogenic growth of the APL and ALL cell lines without inducing immediate apoptosis, but associated with induction of phenotypic differentiation.
  • These data suggest that induction of leukemia progenitor differentiation plays an important role in the mechanism of action of maintenance therapy in ALL.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):774-80 [12610173.001]
  • [Cites] Br J Haematol. 2003 Apr;121(2):251-8 [12694246.001]
  • [Cites] N Engl J Med. 2003 Jun 12;348(24):2375-6 [12802021.001]
  • [Cites] Nouv Rev Fr Hematol. 1984;26(6):371-8 [6597407.001]
  • [Cites] Cancer. 1987 Apr 1;59(7):1258-63 [3469011.001]
  • [Cites] Blood. 1987 Jun;69(6):1551-62 [3555647.001]
  • [Cites] J Clin Oncol. 1989 Dec;7(12):1816-23 [2585022.001]
  • [Cites] N Engl J Med. 1990 Jul 5;323(1):17-21 [2355954.001]
  • [Cites] Blood. 1991 Mar 1;77(5):1080-6 [1995093.001]
  • [Cites] Leukemia. 1991 May;5(5):425-31 [2033963.001]
  • [Cites] Br J Cancer. 1991 Jul;64(1):169-73 [1854617.001]
  • [Cites] Leukemia. 1992;6 Suppl 2:178-81 [1578927.001]
  • [Cites] Leukemia. 1994 Oct;8(10):1744-9 [7934171.001]
  • [Cites] J Pharmacol Exp Ther. 1994 Oct;271(1):193-9 [7965714.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1151-68 [7858247.001]
  • [Cites] Blood. 1995 May 15;85(10):2742-6 [7742535.001]
  • [Cites] Lancet. 1996 Jun 29;347(9018):1783-8 [8667921.001]
  • [Cites] J Immunol. 1996 Dec 1;157(11):4908-17 [8943395.001]
  • [Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]
  • [Cites] J Immunol. 1997 Oct 1;159(7):3278-87 [9317126.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3569-77 [9808549.001]
  • [Cites] Leukemia. 1999 Feb;13(2):275-81 [10025902.001]
  • [Cites] Haematologica. 1999 Jan;84(1):36-58 [10091392.001]
  • [Cites] Exp Hematol. 2002 Nov;30(11):1273-82 [12423680.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3893-903 [12124315.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2225-33 [10090931.001]
  • [Cites] Blood. 1985 Jan;65(1):21-31 [3917311.001]
  • [Cites] Exp Cell Res. 1999 Apr 10;248(1):58-73 [10094813.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1192-200 [10438706.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1442-9 [15735032.001]
  • [Cites] Br J Haematol. 2005 Mar;128(6):853-62 [15755292.001]
  • [Cites] Nat Med. 2005 Jun;11(6):630-7 [15908956.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6361-9 [16778214.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • [Cites] Eur J Immunol. 2001 Apr;31(4):1261-7 [11298353.001]
  • [Cites] Immunol Res. 2000;22(2-3):281-98 [11339363.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3925-30 [11389036.001]
  • [Cites] Blood. 2002 Feb 1;99(3):863-71 [11806988.001]
  • [Cites] Oncogene. 2002 May 13;21(21):3496-506 [12032784.001]
  • [Cites] Blood. 2002 Jul 15;100(2):640-6 [12091359.001]
  • [Cites] Cell Growth Differ. 2002 Jun;13(6):275-83 [12114217.001]
  • [Cites] Pharmacol Ther. 2003 Dec;100(3):257-90 [14652113.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8955-61 [14695213.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2919-25 [15242869.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Feb;68(2):378-82 [5277089.001]
  • [Cites] Lancet. 1973 Jun 16;1(7816):1339-43 [4122739.001]
  • [Cites] Eur J Cancer. 1977 Apr-May;13(4-5):377-9 [194778.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 May;75(5):2458-62 [276884.001]
  • [Cites] Cancer Res. 1984 Jun;44(6):2421-9 [6586286.001]
  • [Cites] Blood. 1984 Oct;64(4):922-9 [6206904.001]
  • (PMID = 17611566.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA015396; United States / NCI NIH HHS / CA / P01 CA070970; United States / NCI NIH HHS / CA / K23 CA107040-04; United States / NCI NIH HHS / CA / K23 CA107040; United States / NCI NIH HHS / CA / P01 CA70970; United States / NCI NIH HHS / CA / P01 CA15396; United States / NCI NIH HHS / CA / CA107040-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Cytotoxins; 5688UTC01R / Tretinoin; E7WED276I5 / 6-Mercaptopurine; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ NIHMS81581; NLM/ PMC2643128
  •  go-up   go-down


73. Greco TP, Conti-Kelly AM, Greco T Jr, Doyle R, Matsuura E, Anthony JR, Lopez LR: Newer antiphospholipid antibodies predict adverse outcomes in patients with acute coronary syndrome. Am J Clin Pathol; 2009 Oct;132(4):613-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Newer antiphospholipid antibodies predict adverse outcomes in patients with acute coronary syndrome.
  • We studied 344 patients with acute coronary syndromes; approximately 40% were aPL+ in 1 or more tests and 60% aPL-.
  • In 215 patients, coronary artery disease (CAD) was angiographically documented, with 43.7% positive for aPL vs 34.9% of patients without CAD positive for aPLs.
  • Anti-beta(2)-glycoprotein I (beta2GPI; 54%) and anti-oxidized low-density lipoprotein (oxLDL)/beta2GPI (48%) were most frequent, accounting for 87% of all aPL+ CAD cases. aPLs correlated with severity of CAD (P = .012).
  • Adverse events occurred in 16.7% of patients with CAD, more frequently in patients who were aPL+ (P = .0006; relative risk, 2.9; 95% confidence interval, 1.5-5.6).
  • Patients who were aPL+ with severe CAD had more adverse events than patients who were aPL- with severe CAD (P = .005) and aPL+ patients undergoing revascularization procedures (P = .001).
  • Vascular events occurred in 21.7% of aPL+ patients compared with 7.1% of aPL- patients (P = .005).
  • [MeSH-major] Acute Coronary Syndrome / immunology. Antibodies, Antiphospholipid / immunology. Coronary Artery Disease / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Antiphospholipid Syndrome / immunology. Female. Humans. Lipoproteins, LDL / immunology. Male. Middle Aged. Prognosis. Prospective Studies. Treatment Outcome. beta 2-Glycoprotein I / immunology

  • Genetic Alliance. consumer health - Antiphospholipid Syndrome.
  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19762540.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Lipoproteins, LDL; 0 / beta 2-Glycoprotein I; 0 / oxidized low density lipoprotein
  •  go-up   go-down


74. Zhou J, Shi J, Hou J, Cao F, Zhang Y, Rasmussen JT, Heegaard CW, Gilbert GE: Phosphatidylserine exposure and procoagulant activity in acute promyelocytic leukemia. J Thromb Haemost; 2010 Apr;8(4):773-82
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphatidylserine exposure and procoagulant activity in acute promyelocytic leukemia.
  • BACKGROUND: Acute promyelocytic leukemia (APL) frequently causes disseminated intravascular coagulation that can worsen with cytotoxic chemotherapy but improve with the therapeutic differentiating agents, all trans retinoic acid (ATRA) and arsenic trioxide (As(2)O(3)).
  • APL cells display tissue factor but the relationship of tissue factor and other procoagulant activity to phosphatidylserine (PS) exposure is largely unknown.
  • METHODS: Lactadherin, a milk protein with stereospecific binding to phosphatidyl-L-serine, was used as a probe for PS exposure on an immortalized APL cell line (NB4) and on the cells of eight patients with APL.
  • RESULTS: Plasma procoagulant activity of NB4 and APL cells increased approximately 15-fold after exposure to etoposide or daunorubicin and decreased 80% after treatment with ATRA or As(2)O(3).
  • Procoagulant activity corresponded to exposed PS on viable APL cells.
  • Excess lactadherin inhibited 80-85% of intrinsic FXase, FVIIa-tissue factor and prothrombinase activities on both NB4 cells and APL cells.
  • CONCLUSIONS: PS is exposed on viable APL cells and is necessary for approximately 80% of procoagulant activity.
  • [MeSH-major] Blood Coagulation. Cell Membrane / metabolism. Leukemia, Promyelocytic, Acute / blood. Phosphatidylserines / metabolism
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / pharmacology. Arsenicals / pharmacology. Blood Coagulation Tests. Cell Differentiation / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Daunorubicin / pharmacology. Etoposide / pharmacology. Factor Xa / metabolism. Female. Flow Cytometry. Humans. Male. Membrane Glycoproteins / metabolism. Microscopy, Confocal. Milk Proteins / metabolism. Oxides / pharmacology. Thrombin / metabolism. Thromboplastin / metabolism. Tretinoin / pharmacology. Young Adult

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20102487.001).
  • [ISSN] 1538-7836
  • [Journal-full-title] Journal of thrombosis and haemostasis : JTH
  • [ISO-abbreviation] J. Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Membrane Glycoproteins; 0 / Milk Proteins; 0 / Oxides; 0 / PAS-6-7 glycoprotein, Bos taurus; 0 / Phosphatidylserines; 5688UTC01R / Tretinoin; 6PLQ3CP4P3 / Etoposide; 9035-58-9 / Thromboplastin; EC 3.4.21.5 / Thrombin; EC 3.4.21.6 / Factor Xa; S7V92P67HO / arsenic trioxide; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


75. Peerschke EI, Yin W, Alpert DR, Roubey RA, Salmon JE, Ghebrehiwet B: Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies. Lupus; 2009 May;18(6):530-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A cross-sectional retrospective analysis was performed to evaluate serum complement fixation on platelets and thrombotic incidence using banked sera and clinical data from patients with SLE (n = 91), SLE with antiphospholipid antibodies (aPL) or APS (n = 78) and primary aPL (n = 57) or APS (n = 96).
  • Enhanced in-situ complement fixation was associated with the presence of IgG aPL and IgG anti-beta2 glycoprotein 1 antibodies (P < 0.05) and increased platelet activation (P < 0.005).
  • Moreover, enhanced complement fixation, especially C4d deposition on heterologous platelets, was positively associated with arterial thrombotic events in patients with SLE and aPL (P = 0.039).
  • Sera from patients with aPL possess an enhanced capacity for in-situ complement fixation on platelets.

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Thrombosis.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Lupus.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunopharmacology. 2000 Mar;46(3):209-22 [10741901.001]
  • [Cites] Scand J Rheumatol. 2006 Mar-Apr;35(2):85-95 [16641040.001]
  • [Cites] J Autoimmun. 2000 Sep;15(2):145-51 [10968901.001]
  • [Cites] Curr Rheumatol Rep. 2000 Jun;2(3):238-45 [11123065.001]
  • [Cites] Nat Med. 2006 Jun;12(6):682-7 [16715088.001]
  • [Cites] J Rheumatol. 2006 Sep;33(9):1715-7 [16960931.001]
  • [Cites] J Thromb Haemost. 2006 Sep;4(9):2035-42 [16961611.001]
  • [Cites] Blood. 2007 Jan 15;109(2):422-30 [16985176.001]
  • [Cites] J Thromb Haemost. 2007 Feb;5(2):369-77 [17096706.001]
  • [Cites] Am J Pathol. 2007 Sep;171(3):715-27 [17640961.001]
  • [Cites] Atherosclerosis. 2007 Nov;195(1):90-9 [17234193.001]
  • [Cites] Autoimmunity. 2007 Dec;40(8):560-6 [18075790.001]
  • [Cites] Ann Rheum Dis. 2008 Mar;67(3):395-401 [17644539.001]
  • [Cites] Circ Res. 2002 Jan 11;90(1):29-37 [11786515.001]
  • [Cites] N Engl J Med. 2002 Mar 7;346(10):752-63 [11882732.001]
  • [Cites] Curr Dir Autoimmun. 2004;7:133-48 [14719378.001]
  • [Cites] Clin Exp Immunol. 2004 Jun;136(3):393-401 [15147339.001]
  • [Cites] Thromb Res. 2004;114(5-6):329-34 [15507262.001]
  • [Cites] Blood. 1980 May;55(5):841-7 [6767512.001]
  • [Cites] Blood. 1982 Jul;60(1):71-7 [6282365.001]
  • [Cites] Arthritis Rheum. 1982 Nov;25(11):1271-7 [7138600.001]
  • [Cites] N Engl J Med. 1987 Jun 11;316(24):1525-30 [3295544.001]
  • [Cites] Clin Exp Immunol. 1988 Sep;73(3):484-8 [2463123.001]
  • [Cites] J Biol Chem. 1989 Nov 15;264(32):19228-35 [2808422.001]
  • [Cites] Clin Exp Rheumatol. 1992 Sep-Oct;10(5):455-60 [1458697.001]
  • [Cites] Blood. 1993 Mar 1;81(5):1255-62 [8443387.001]
  • [Cites] Am J Clin Pathol. 1994 May;101(5):616-24 [7909979.001]
  • [Cites] J Immunol. 1994 Aug 1;153(3):1328-32 [8027560.001]
  • [Cites] Scand J Immunol. 1995 May;41(5):427-32 [7725061.001]
  • [Cites] Trends Pharmacol Sci. 1995 Jun;16(6):198-204 [7652929.001]
  • [Cites] J Clin Invest. 1995 Nov;96(5):2211-9 [7593607.001]
  • [Cites] Lupus. 1996 Oct;5(5):386-7 [8902766.001]
  • [Cites] Thromb Haemost. 1997 Feb;77(2):394-8 [9157602.001]
  • [Cites] J Rheumatol. 1999 Mar;26(3):591-6 [10090168.001]
  • [Cites] Circulation. 1999 Apr 20;99(15):1997-2002 [10209004.001]
  • [Cites] Arthritis Rheum. 1999 Jul;42(7):1309-11 [10403256.001]
  • [Cites] Nat Clin Pract Cardiovasc Med. 2005 Aug;2(8):423-30 [16119705.001]
  • [Cites] Lupus. 2005;14(12):953-8 [16425575.001]
  • [Cites] Arthritis Rheum. 2006 Feb;54(2):670-4 [16447243.001]
  • [Cites] Adv Immunol. 2000;76:227-324 [11079100.001]
  • (PMID = 19395455.001).
  • [ISSN] 0961-2033
  • [Journal-full-title] Lupus
  • [ISO-abbreviation] Lupus
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI060866-03; United States / NIAID NIH HHS / AI / R01 AI060866-03; United States / NHLBI NIH HHS / HL / HL67211; United States / NIAID NIH HHS / AI / AI060866; United States / NHLBI NIH HHS / HL / R01 HL067211
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Complement C4; 80295-33-6 / Complement C1q
  • [Other-IDs] NLM/ NIHMS87717; NLM/ PMC2707931
  •  go-up   go-down


76. Zimmermann-Górska I, Grodecka-Gazdecka S, Białkowska-Puszczewicz G, Puszczewicz M, Goździecka M, Kondarewicz P: [Anticardiolipin and anti-beta2 glycoprotein-1 antibodies patients with breast carcinoma: a pilot study]. Pol Arch Med Wewn; 2007;117 Suppl:24-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Evaluation of prevalence of some antiphospholipid antibodies (aPL) in serum of patients with breast carcinoma and the possible correlation between aPL seropositivity and clinical symptoms.
  • CONCLUSIONS: We have not observed a difference of aPL prevalence between the group of patients with breast carcinoma and controls.
  • The association of breast cancer and aPL seropositivity deserves further investigations.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Pilot Projects. Reference Values. Risk Factors

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18778015.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibodies, Anticardiolipin; 0 / Anticoagulants; 0 / beta 2-Glycoprotein I
  •  go-up   go-down


77. Touré AO, Doupa D, Diop S, Kane A, Kane A, Ka MM, Dieye T, Thiam D, Diakhaté L: [Relation between lupus-antiphospholipids antibodies and heart disorders]. Ann Biol Clin (Paris); 2006 May-Jun;64(3):231-5
MedlinePlus Health Information. consumer health - Lupus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIM: Antiphospholipids antibodies (APL) are autoantibodies found in lupus erythematosus and disorders like.
  • An increased frequency of cardiac disorders in antiphospholipids (APL) positive lupus has been reported.
  • The aim of our study was to evaluate the role of APL as an independent risk factor of cardiac disorders in patients with systemic lupus erythematosus.
  • RESULTS: 37 patients affected by lupus were included in this study with a net feminine prevalence (89%); 8 (14.6%) had APL's significant results and 20 presented an echographic heart abnormality.
  • The analysis of our data did not reveal an increased risk of cardiac diseases among APL positive lupic patients as compared to the negative group (p = 1).
  • CONCLUSION: The presence of APL in patients with systemic lupus does not so seem to be an independant risk factor of heart diseases.
  • [MeSH-minor] Adolescent. Adult. Aged. Cross-Sectional Studies. Female. Humans. Male. Middle Aged. Prospective Studies

  • Genetic Alliance. consumer health - Lupus.
  • MedlinePlus Health Information. consumer health - Heart Disease in Women.
  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16698558.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid
  •  go-up   go-down


78. Paul S, Das S: Multiple tendons of abductor pollicis longus muscle: a cadaveric study with clinical implications. Kathmandu Univ Med J (KUMJ); 2006 Oct-Dec;4(4):501-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abductor pollicis longus (APL) muscle is known to exhibit numerous variations.
  • Variations in the number of tendons of APL muscle may be asymptomatic and are often incidental findings.
  • The present case report, detected in a 42 year male cadaver, describes the APL muscle having three tendons.
  • In a wider perspective, variations in the number of tendons of APL may also be important for anthropological correlation and academic studies.
  • [MeSH-minor] Adult. Cadaver. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18603962.001).
  • [ISSN] 1812-2078
  • [Journal-full-title] Kathmandu University medical journal (KUMJ)
  • [ISO-abbreviation] Kathmandu Univ Med J (KUMJ)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


79. Jácomo RH, Melo RA, Souto FR, de Mattos ER, de Oliveira CT, Fagundes EM, Bittencourt HN, Bittencourt RI, Bortolheiro TC, Paton EJ, Bendlin R, Ismael S, Chauffaille Mde L, Silva D, Pagnano KB, Ribeiro R, Rego EM: Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica; 2007 Oct;92(10):1431-2
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines.
  • We report an increased incidence of high relapse risk features in 157 APL Brazilian patients.
  • [MeSH-major] Anthracyclines / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / pathology. Tretinoin / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Brazil / epidemiology. Child. Child, Preschool. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18024380.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anthracyclines; 5688UTC01R / Tretinoin
  •  go-up   go-down


80. Avcin T, Silverman ED: Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome. Lupus; 2007;16(8):627-33
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The major differences between pediatric and adult APS include absence of common acquired risk factors for thrombosis, absence of pregnancy-related morbidity, increased incidence of infection-induced antibodies, differences in cut-off values for determination of aPL and specific factors regarding long-term therapy in children.
  • The presence of aPL in pediatric SLE can modify the disease expression and may be an important predictor of the development of irreversible organ damage.
  • Two recently established international registries of neonates and children with APS provide a good opportunity to conduct large, prospective studies on the clinical significance of aPL and long-term outcome of pediatric APS.


81. Gale RE, Hills R, Pizzey AR, Kottaridis PD, Swirsky D, Gilkes AF, Nugent E, Mills KI, Wheatley K, Solomon E, Burnett AK, Linch DC, Grimwade D, NCRI Adult Leukaemia Working Party: Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood; 2005 Dec 1;106(12):3768-76
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.
  • The prognostic significance of FLT3 mutations in acute promyelocytic leukemia (APL) is not firmly established and is of particular interest given the opportunities for targeted therapies using FLT3 inhibitors.
  • We studied 203 patients with PML-RARA-positive APL; 43% of the patients had an FLT3 mutation (65 internal tandem duplications [ITDs], 19 D835/I836, 4 ITD+D835/I836).
  • FLT3/ITDs were correlated with M3v subtype (P < .001), bcr3 PML breakpoint (P < .001), and expression of reciprocal RARA-PML transcripts (P = .01).
  • In in vitro differentiation assays using primary APL blasts (n = 6), the FLT3 inhibitor CEP-701 had a greater effect on cell survival/proliferation in FLT3/ITD+ cells, but this inhibition was reduced in the presence of ATRA.
  • These data carry implications for the use of FLT3 inhibitors as frontline therapy for APL.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carbazoles / pharmacology. Indoles / pharmacology. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / genetics. fms-Like Tyrosine Kinase 3 / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Gene Expression Profiling. Humans. Infant. Male. Middle Aged. Mutation. Oligonucleotide Array Sequence Analysis. Prognosis. Survival Analysis. Tretinoin / pharmacology

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16105978.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carbazoles; 0 / Indoles; 5688UTC01R / Tretinoin; DO989GC5D1 / lestaurtinib; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


82. Ibrahim FA, Yassin MA, El-Ayoubi HR, Alhiji IA, Albinali AS, Almansour SM, Qafoud FM: Clinico-pathological profile of acute promyelocytic leukaemia at Al-Amal Oncology-Haematology Centre, Qatar. East Mediterr Health J; 2010 Sep;16(9):958-65

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinico-pathological profile of acute promyelocytic leukaemia at Al-Amal Oncology-Haematology Centre, Qatar.
  • This cases series describes the profile of adult patients with acute promyelocytic leukaemia (APt) at a referral hospital in Qatar.
  • Of 34 acute myeloid leukaemia (AML) cases diagnosed, 11(32%) were classified as APt.
  • Translocation t(15;17) was detected in 63% of cases.
  • APL constitutes a high proportion of AML cases in Qatar, with considerable morphological heterogeneity and a oredominance of APL variants with unfavourable oresenting features.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / epidemiology. Leukemia, Promyelocytic, Acute / pathology
  • [MeSH-minor] Adolescent. Anemia / epidemiology. Anemia / etiology. Bone Marrow Examination. Cancer Care Facilities. Cytogenetic Analysis. Female. Flow Cytometry. Genetic Variation / genetics. Humans. Immunophenotyping. Karyotyping. Leukocytosis / epidemiology. Leukocytosis / etiology. Male. Middle Aged. Population Surveillance. Qatar / epidemiology. Thrombocytopenia / epidemiology. Thrombocytopenia / etiology. Translocation, Genetic. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21218723.001).
  • [ISSN] 1020-3397
  • [Journal-full-title] Eastern Mediterranean health journal = La revue de santé de la Méditerranée orientale = al-Majallah al-ṣiḥḥīyah li-sharq al-mutawassiṭ
  • [ISO-abbreviation] East. Mediterr. Health J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


83. Pascut D, Princi T, Donato M, Tamaro G, Parco S: Antiphospholipid antibodies and lipoprotein(a) in obese children. Acta Paediatr; 2009 Apr;98(4):703-7
MedlinePlus Health Information. consumer health - Obesity in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: Antiphospholipid (aPL) antibodies, Lipoprotein(a) [Lp(a)] and obesity are considered three independent risk factors for development of cardiovascular diseases.
  • We investigate the presence of aPL antibodies and the Lp(a) concentration in 190 obese and 30 healthy children divided into prepubertal and pubertal, compared with healthy adults.
  • RESULTS: aPL antibodies were detected in 2.65% of prepubertal and in 2.59% of pubertal obese children.
  • Considering results obtained by Lp(a) test, 4.4% of prepubertal and 5.2% of pubertal obese children and 17.5% of healthy adults were at risk for development of cardiovascular diseases.
  • Considering aPL antibodies there is no statistically significant difference among the different considered groups; therefore each category has the same risk factor.
  • These results suggest the control of BMI in young population to avoid the presence of the obesity as another independent prothrombotic risk factor to be added to aPL and Lp(a) in the future adulthood.
  • [MeSH-minor] Adolescent. Adult. Body Mass Index. Cardiovascular Diseases / blood. Case-Control Studies. Child. Child, Preschool. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Puberty / blood. Risk Factors

  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19183123.001).
  • [ISSN] 1651-2227
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Lipoprotein(a)
  •  go-up   go-down


84. Bhattacharyya M, Chatterjee T, Panigrahi I, Kannan M, Choudhry VP, Mahapatra M, Saxena R: Therapy-related acute promyelocytic leukemia after treatment of carcinoma breast--a case report. Indian J Pathol Microbiol; 2006 Apr;49(2):251-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute promyelocytic leukemia after treatment of carcinoma breast--a case report.
  • We report a 43-year-old female, with acute promyelocytic leukemia occurring after 9 months of treatment for carcinoma breast.
  • The diagnosis of APL was made on morphology, cytogenetics and molecular studies.
  • In contrast to other published report of therapy related APL (tAPL) the present case presented early after the primary malignancy and underwent a rapid, downhill course.
  • [MeSH-major] Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / therapy. Leukemia, Promyelocytic, Acute / etiology. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adult. Female. Humans. Time Factors

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933728.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 15
  •  go-up   go-down


85. Saha SP, Bhattacharjee N, Ganguli RP, Sil S, Patra KK, Sengupta M, Barui G, Goswami BK: Prevalence and significance of antiphospholipid antibodies in selected at-risk obstetrics cases: a comparative prospective study. J Obstet Gynaecol; 2009 Oct;29(7):614-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a prospective comparative study we screened 112 women with a past history either of pre-eclampsia, eclampsia, recurrent abortion, IUGR, IUFD or abruptio placentae, with no apparent aetiology and a demographically matched cohort of 106 women having a past history of uncomplicated pregnancy outcome for the presence of antiphospholipid antibodies (aPL) and their significance.
  • In the former group, the prevalence of aPL ranged from 10-46.87% compared with 8.49% in the later group.
  • In women with the presence of aPL, the incidence of pre-eclampsia, early onset pre-eclampsia and abruptio placentae were 25%, 14.58% and 18.75%, respectively.
  • Fetal morbidity rates were also higher in the mothers with aPL positivity, the incidence of IUGR was 27.08% and oligohydramnios was 33.33% in them.
  • All these complications were statistically significant when compared with those of aPL negative mothers.
  • [MeSH-minor] Adult. Antiphospholipid Syndrome / epidemiology. Female. Humans. Incidence. India / epidemiology. Pregnancy. Pregnancy Outcome. Prevalence. Prospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19757265.001).
  • [ISSN] 1364-6893
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Anticardiolipin; 0 / Lupus Coagulation Inhibitor
  •  go-up   go-down


86. Maruyama M, Takahara M, Kikuchi N, Ito K, Watanabe T, Ogino T: De Quervain disease caused by abductor pollicis longus tenosynovitis: a report of three cases. Hand Surg; 2009;14(1):43-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We encountered three cases in which EPB tenosynovitis was absent and abductor pollicis longus (APL) tenosynovitis was confirmed during operation.
  • In the treatment of de Quervain disease, APL tenosynovitis should be paid as much attention as EPB tenosynovitis.
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19598322.001).
  • [ISSN] 0218-8104
  • [Journal-full-title] Hand surgery : an international journal devoted to hand and upper limb surgery and related research : journal of the Asia-Pacific Federation of Societies for Surgery of the Hand
  • [ISO-abbreviation] Hand Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


87. Shen H, Li R, Xiao H, Zhou Q, Cui Q, Chen J: Higher serum clozapine level is associated with increased antiphospholipid antibodies in schizophrenia patients. J Psychiatr Res; 2009 Mar;43(6):615-9
Hazardous Substances Data Bank. CLOZAPINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: This study was to evaluate the relationship between clozapine and aPL in schizophrenia patients.
  • A fasting blood sample was taken for serum aPL and serum clozapine level.
  • Serum aPL were measured by ELISA technique and HPLC method was used for the determination of serum clozapine level.
  • RESULTS: The unmedicated schizophrenia patients showed higher IgG aCL level [mean+/-SD: 1.51+/-0.81 and 1.25+/-0.13 U, respectively (t=2.77, df=111, p<0.01)] and IgM aCL level [mean+/-SD: 1.53+/-0.54. and 1.33+/-0.15 U, respectively (t=-2.98, df=111, p<0.01)] compared with the healthy controls.
  • The comparison of the clozapine-treated schizophrenia patients and the healthy controls showed significant difference in IgG aCL level [mean+/-SD: 1.74+/-0.90 and 1.25+/-0.13 U, respectively (t=-4.77, df=124, p<0.01)] and IgM aCL level [mean+/-SD: 1.62+/-0.83 and 1.33+/-0.15 U, respectively (t=-4.35, df=124, p<0.01)].
  • CONCLUSIONS: A higher serum clozapine level is associated with an increased aPL in schizophrenia patients.
  • [MeSH-minor] Adult. Chromatography, High Pressure Liquid / methods. Enzyme-Linked Immunosorbent Assay / methods. Female. Humans. Immunoglobulin G / blood. Immunoglobulin M / blood. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976782.001).
  • [ISSN] 0022-3956
  • [Journal-full-title] Journal of psychiatric research
  • [ISO-abbreviation] J Psychiatr Res
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Antipsychotic Agents; 0 / Immunoglobulin G; 0 / Immunoglobulin M; J60AR2IKIC / Clozapine
  •  go-up   go-down


88. Jeffery RC, Narshi CB, Isenberg DA: Prevalence, serological features, response to treatment and outcome of critical peripheral ischaemia in a cohort of lupus patients. Rheumatology (Oxford); 2008 Sep;47(9):1379-83
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Seven out of 485 patients (1.4%) had evidence of gangrene or CPI with onset at any stage of SLE disease from presenting feature to 27 yrs after SLE onset, aPL and LAC were over-represented in the CPI patients.
  • All seven were treated with intravenous (IV) epoprostenol infusion and aPL-positive patients were anti-coagulated.
  • CONCLUSION: CPI is a rare but potentially devastating complication of SLE associated with aPL, LAC and active SLE.
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antirheumatic Agents / therapeutic use. Female. Gangrene / drug therapy. Gangrene / etiology. Humans. Male. Retrospective Studies. Risk Factors. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Lupus.
  • MedlinePlus Health Information. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Rheumatology (Oxford). 2009 Apr;48(4):451-2 author reply 452-3 [19151032.001]
  • (PMID = 18586769.001).
  • [ISSN] 1462-0332
  • [Journal-full-title] Rheumatology (Oxford, England)
  • [ISO-abbreviation] Rheumatology (Oxford)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antirheumatic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


89. Jeddi R, Kacem K, Ben Lakhal R, Aissaoui L, Ben Abid H, Belhadj Ali Z, Meddeb B: [Pseudotumor cerebri with all-trans retinoic acid. A case report]. Tunis Med; 2006 Dec;84(12):827-9
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is an uncommon complication of all-trans-retinoic acid (ATRA) therapy in children treated for acute promyelocytic leukaemia (APL).
  • Its occurrence is rare among adult patients with APL and treated with ATRA .
  • We report a case of an adult with APL who developed PC during induction therapy with ATRA-PC was managed with repeated lumbar punctures and corticotherapy.
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Pseudotumor cerebri.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17288291.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


90. Zhu HH, Liu YR, Qin YZ, Li JL, Chang Y, Wang YZ, Shan FX, Jiang B, Lu DP: [Detection of PML/RARalpha gene transcripts in 46 newly diagnosed acute promyelocytic leukemia patients by real-time quantitative reverse-transcription polymerase chain reaction]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb;15(1):1-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of PML/RARalpha gene transcripts in 46 newly diagnosed acute promyelocytic leukemia patients by real-time quantitative reverse-transcription polymerase chain reaction].
  • In order to explore the application of real-time quantitative reverse-transcription polymerase chain reaction (Q-PCR) for detecting PML/RARalpha gene transcripts in patients with acute promyelocytic leukemia (APL), the bone marrow samples from 46 newly diagnosed APL patients were collected for analysis.
  • Three plasmids containing cDNA fragments of the bcr1-, bcr3-form PML/RARalpha and ABL control gene were constructed respectively.
  • PML/RARalpha mRNA was detected by Q-PCR in 46 APL patients and 40 non-APL patients.
  • The normalized quotient (NQ) of PML/RARalpha mRNA was calculated as followings: NQ = PML/RARalpha mRNA copy numbers/ABL mRNA copy numbers.
  • Immunophenotype of acute promyelocytic leukemia was determined by four-color flow cytometry.
  • The median NQ of PML/RARalpha mRNA was 0.450 (0.084 - 1.082) in 46 APL patients.
  • There was no indication of any correlation of PML/RARalpha mRNA type with age, sex, hemoglobin, platelet count, percentage of promyelocytes in bone marrow detected by morphology or flow cytometry, PML/RARalpha NQ, or signs of clinically diagnosed coagulation/bleeding disorders.
  • Compared with bcr1-form cases, bcr3-form cases had more M(3v) phenotype (42.9% vs 9.4%, P = 0.015) and higher WBC count (9.35 x 10(9)/L vs 2.15 x 10(9)/L, P = 0.038).
  • APL cells could be classified into large side scatter population (L-SSC) and non-large side scatter population (NL-SSC) in CD45/SSC histogram of flow cytometry.
  • The median NQ of PML/RARalpha mRNA was 0.450 in newly diagnosed APL patients.
  • There was no significant difference about PML/RARalpha mRNA expression of both bcr3-form and bcr1-form APL patients.
  • Type of PML/RARalpha transcripts is related with the morphology and immunophenotype.

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17490509.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / Receptors, Retinoic Acid; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
  •  go-up   go-down


91. Ulander VM, Stefanovic V, Masuda J, Suzuki K, Hiilesmaa V, Kaaja R: Plasma levels of annexins IV and V in relation to antiphospholipid antibody status in women with a history of recurrent miscarriage. Thromb Res; 2007;120(6):865-70
Genetic Alliance. consumer health - Recurrent spontaneous abortion.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The presence of antiphospholipid (aPL) antibodies increases the risk for recurrent miscarriage (RM).
  • The aim of our study was to define plasma concentrations of circulating annexins IV and V at the beginning of pregnancy among women with a history of RM, and in connection to their aPL antibody status.
  • Plasma levels of annexin V were significantly higher at the beginning of pregnancy (P=0.03), at the 6th (P=0.01) and 8th week of pregnancy in women with aPL antibodies compared with those without aPL antibodies.
  • Plasma levels of annexin IV at the first visit in women with aPL antibodies were similar to those at 6 and 8 weeks of gestation.
  • There were no significant differences in plasma annexin IV levels between women with and without aPL antibodies.
  • CONCLUSIONS: Patients with RM show elevated plasma levels of annexin V in presence of aPL antibodies.
  • [MeSH-minor] Adult. Enzyme-Linked Immunosorbent Assay. Female. Humans. Pregnancy. Pregnancy Outcome. Prognosis. Thrombophilia / blood. Thrombophilia / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17363042.001).
  • [ISSN] 0049-3848
  • [Journal-full-title] Thrombosis research
  • [ISO-abbreviation] Thromb. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A4; 0 / Annexin A5; 0 / Antibodies, Antiphospholipid
  •  go-up   go-down


92. Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA: Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood; 2010 Nov 11;116(19):3751-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.
  • Arsenic trioxide (As(2)O(3)) is a highly effective treatment for patients with relapsed acute promyelocytic leukemia (APL); its role as consolidation treatment for patients in first remission has not been defined.
  • We randomized 481 patients (age ≥ 15 years) with untreated APL to either a standard induction regimen of tretinoin, cytarabine, and daunorubicin, followed by 2 courses of consolidation therapy with tretinoin plus daunorubicin, or to the same induction and consolidation regimen plus two 25-day courses of As(2)O(3) consolidation immediately after induction.
  • The addition of As(2)O(3) consolidation to standard induction and consolidation therapy significantly improves event-free and disease-free survival in adults with newly diagnosed APL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Arsenicals / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / administration & dosage
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adolescent. Adult. Aged. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Disease-Free Survival. Female. Humans. Male. Methotrexate / administration & dosage. Middle Aged. North America. Survival Analysis. Treatment Outcome. Tretinoin / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 1;94(9):3015-21 [10556184.001]
  • [Cites] J Clin Oncol. 2009 Jun 1;27(16):2668-76 [19414681.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3852-60 [11559723.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3609-15 [14512391.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1237-43 [14576047.001]
  • [Cites] J Thromb Haemost. 2004 Aug;2(8):1341-50 [15304040.001]
  • [Cites] Blood. 1980 Nov;56(5):773-81 [6932977.001]
  • [Cites] Am J Med. 1984 May;76(5):827-41 [6586073.001]
  • [Cites] Am J Hematol. 1989 Apr;30(4):221-7 [2539013.001]
  • [Cites] Hematol Pathol. 1989;3(1):23-8 [2745357.001]
  • [Cites] J Clin Oncol. 1990 May;8(5):813-9 [2185339.001]
  • [Cites] J Clin Oncol. 1990 Nov;8(11):1913-21 [2230879.001]
  • [Cites] N Engl J Med. 1993 Jul 15;329(3):177-89 [8515790.001]
  • [Cites] Blood. 1994 Jan 1;83(1):10-25 [8274729.001]
  • [Cites] Br J Haematol. 1994 Mar;86(3):451-60 [8043428.001]
  • [Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1014-21 [9242531.001]
  • [Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1341-8 [9801394.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1192-200 [10438706.001]
  • [Cites] Control Clin Trials. 1999 Oct;20(5):395-407 [10503800.001]
  • [Cites] Ann Oncol. 2006 Jan;17(1):131-4 [16227315.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2627-32 [16352810.001]
  • [Cites] Blood. 2006 May 1;107(9):3469-73 [16373661.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5703-10 [17116939.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1078-84 [17975017.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3130-4 [18664623.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):504-10 [19075265.001]
  • [Cites] Blood. 2009 Feb 26;113(9):1875-91 [18812465.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3342-7 [19225113.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1247-53 [10942364.001]
  • (PMID = 20705755.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00003934
  • [Grant] United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA33601
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin; E7WED276I5 / 6-Mercaptopurine; S7V92P67HO / arsenic trioxide; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ PMC2981533
  •  go-up   go-down


93. Chen DY, Tzang BS, Chen YM, Lan JL, Tsai CC, Hsu TC: The association of anti-parvovirus B19-VP1 unique region antibodies with antiphospholipid antibodies in patients with antiphospholipid syndrome. Clin Chim Acta; 2010 Aug 5;411(15-16):1084-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Absorption experiments were performed using B19-VP1u protein to determine the binding specificity of antiphospholipid antibodies (aPL).
  • CONCLUSIONS: We show a close association of B19 infection with aPL production and suggest B19-VP1u may be of pathogenetic importance in some patients with APS.
  • [MeSH-minor] Absorption. Adult. DNA, Viral / blood. Female. Humans. Immunoglobulin G / blood. Immunoglobulin G / immunology. Immunoglobulin M / blood. Immunoglobulin M / immunology. Male

  • Genetic Alliance. consumer health - Antiphospholipid Syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20385113.001).
  • [ISSN] 1873-3492
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Capsid Proteins; 0 / DNA, Viral; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / capsid protein VP1, parvovirus B19
  •  go-up   go-down


94. Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, Testa S, Marongiu F, Bison E, Denas G, Banzato A, Padayattil Jose S, Iliceto S: Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost; 2010 Feb;8(2):237-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The characteristics and the clinical course of antiphospholipid syndrome (APS) in high-risk patients that are positive for all three recommended tests that detect the presence of antiphospholipid (aPL) antibodies have not been described.
  • METHODS: This retrospective analysis of prospectively collected data examined patients referred to Italian Thrombosis Centers that were diagnosed with definite APS and tested positive for aPL [lupus anticoagulant (LA), anti-cardiolipin (aCL), and anti-beta2-glycoprotein I (beta2GPI) antibodies].
  • CONCLUSIONS: Patients with APS and triple positivity for aPL are at high risk of developing future thromboembolic events.
  • [MeSH-minor] Administration, Oral. Adult. Aged. Antibodies, Anticardiolipin / blood. Anticoagulants / administration & dosage. Anticoagulants / adverse effects. Biomarkers / blood. Catastrophic Illness. Disease Progression. Female. Hemorrhage / chemically induced. Humans. Incidence. Italy. Kaplan-Meier Estimate. Lupus Coagulation Inhibitor / blood. Male. Middle Aged. Predictive Value of Tests. Pregnancy. Proportional Hazards Models. Recurrence. Retrospective Studies. Risk Assessment. Risk Factors. Time Factors. Treatment Outcome. beta 2-Glycoprotein I / immunology

  • Genetic Alliance. consumer health - Antiphospholipid Syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thromb Haemost. 2010 Feb;8(2):234-6 [19912514.001]
  • (PMID = 19874470.001).
  • [ISSN] 1538-7836
  • [Journal-full-title] Journal of thrombosis and haemostasis : JTH
  • [ISO-abbreviation] J. Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Anticardiolipin; 0 / Antibodies, Antiphospholipid; 0 / Anticoagulants; 0 / Biomarkers; 0 / Lupus Coagulation Inhibitor; 0 / beta 2-Glycoprotein I
  •  go-up   go-down


95. Slavcheva V, Lukanov T, Tzvetkov N: Two cases of extramedullary myeloid tumor in patients with continuous remission of acute myeloblastic leukemia. J BUON; 2008 Oct-Dec;13(4):589-92
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of extramedullary myeloid tumor in patients with continuous remission of acute myeloblastic leukemia.
  • It can be initial manifestation of myeloproliferative disorders or relapse of previously treated acute myeloblastic leukemia (AML).
  • We present two patients, one with AML-M2 and the other with acute promyelocytic leukemia (APL)-M3.
  • The APL-M3 patient was treated with radiotherapy to the involved supraclavicular lymph node which was followed by chemotherapy.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Leukemia, Promyelocytic, Acute / pathology. Sarcoma, Myeloid / pathology
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Recurrence

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19145688.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


96. Nasilowska-Adamska B, Majewski M, Seferynska I, Szczepinski A, Tomaszewska A, Prochorec-Sobieszek M, Guz K, Torbicki A, Warzocha K, Marianska B: Predictive value of RT-PCR PML-RARA transcript monitoring for extramedullary relapse of acute promyelocytic leukemia in the pleura, heart and pericardium after allogeneic SCT. Ann Transplant; 2007;12(3):33-8
Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of RT-PCR PML-RARA transcript monitoring for extramedullary relapse of acute promyelocytic leukemia in the pleura, heart and pericardium after allogeneic SCT.
  • BACKGROUND: We report a patient with acute promyelocytic leukemia (APL) relapse in extremely rare sites--the pleura, heart and pericardium without evidence of bone marrow infiltration and with molecular evidence of disease after allogeneic stem cell transplantation (alloSCT).
  • CASE DESCRIPTION: Presented patient underwent alloSCT in second complete hematological and cytogenetic remission with presence of promyelocytic leukemia-retinoic acid receptor A (PML-RARA) detected in reverse transcription-polymerase chain reaction (RT-PCR) with sensitivity of 10(-2).
  • After transplant, this patient remained in complete hematological and cytogenetic remission but nested RT-PCR assays with detection thresholds of 10(-3)/10(-4) were positive for PML-RARA rearranged gene even chimerism tests showed 100% of donor profile.
  • At that time, PML-RARA transcript detected in RT-PCR assay (10(-2)) was positive for the first time after transplant.
  • CONCLUSIONS: We conclude that detection of PML-RARA after alloSCT should be indication insightful diagnosis of medullary or extramedullary (EM) relapse.
  • The imaging techniques of all possible sites of APL EM relapse have to be included.
  • [MeSH-major] Heart Neoplasms / diagnosis. Leukemia, Promyelocytic, Acute / genetics. Oncogene Proteins, Fusion / genetics. Pleural Neoplasms / diagnosis. Sarcoma, Myeloid / diagnosis. Stem Cell Transplantation
  • [MeSH-minor] Adult. Humans. Male. Pericardium. Predictive Value of Tests. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18290568.001).
  • [ISSN] 1425-9524
  • [Journal-full-title] Annals of transplantation
  • [ISO-abbreviation] Ann. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
  •  go-up   go-down


97. Yang YM, Liu T: [Complete remission of acute promyelocytic leukemia resisting all-trans retinoic acid of one case treated by tanshinone II A]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Nov;37(6):965-7
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete remission of acute promyelocytic leukemia resisting all-trans retinoic acid of one case treated by tanshinone II A].
  • The acute promyelocytic leukemia (APL) with DIC was diagnosed.
  • The tanshinone II A could induce CR of APL with ATRA resistance, no side effect was observed; there is a reoccurring possibility from consolidation therapy with tanshinone II A.
  • [MeSH-major] Drug Resistance, Neoplasm. Leukemia, Promyelocytic, Acute / drug therapy. Phenanthrenes / therapeutic use. Remission Induction / methods. Tretinoin / pharmacology
  • [MeSH-minor] Adult. Diterpenes, Abietane. Humans. Male

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236602.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Diterpenes, Abietane; 0 / Phenanthrenes; 03UUH3J385 / tanshinone; 5688UTC01R / Tretinoin
  •  go-up   go-down


98. Ma DQ, Whitehead PL, Menold MM, Martin ER, Ashley-Koch AE, Mei H, Ritchie MD, Delong GR, Abramson RK, Wright HH, Cuccaro ML, Hussman JP, Gilbert JR, Pericak-Vance MA: Identification of significant association and gene-gene interaction of GABA receptor subunit genes in autism. Am J Hum Genet; 2005 Sep;77(3):377-88
Guide to Pharmacology. gene/protein/disease-specific - GABAA receptor alpha4 subunit - data and references .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the adult brain, has been implicated in autism etiology.
  • Initially, SNPs were used in a family-based study for allelic association analysis--with the pedigree disequilibrium test and the family-based association test--and for genotypic and haplotypic association analysis--with the genotype-pedigree disequilibrium test (geno-PDT), the association in the presence of linkage (APL) test, and the haplotype family-based association test.
  • Further support for this two-locus model came from both the multilocus geno-PDT and the APL test, which indicated a common genotype and haplotype combination positively associated with disease.

  • Genetic Alliance. consumer health - Autism.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bioinformatics. 2000 Feb;16(2):182-3 [10842743.001]
  • [Cites] Am J Hum Genet. 1995 Sep;57(3):717-26 [7668301.001]
  • [Cites] Hum Mol Genet. 1998 Mar;7(3):571-8 [9546821.001]
  • [Cites] Am J Hum Genet. 1998 May;62(5):1077-83 [9545402.001]
  • [Cites] Am J Hum Genet. 1998 Nov;63(5):1531-40 [9867708.001]
  • [Cites] Hum Mol Genet. 1999 May;8(5):805-12 [10196369.001]
  • [Cites] Am J Hum Genet. 1999 Aug;65(2):493-507 [10417292.001]
  • [Cites] Psychol Med. 1999 Jul;29(4):769-86 [10473304.001]
  • [Cites] Trends Genet. 2004 Dec;20(12):640-7 [15522460.001]
  • [Cites] Nat Genet. 2005 Jan;37(1):13-4 [15624016.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] BMC Genet. 2005;6 Suppl 1:S145 [16451605.001]
  • [Cites] Am J Hum Genet. 2000 Jul;67(1):146-54 [10825280.001]
  • [Cites] Mol Psychiatry. 2000 May;5(3):320-2 [10889536.001]
  • [Cites] Am J Med Genet. 2000 Jun 12;96(3):365-72 [10898916.001]
  • [Cites] Am J Med Genet. 2000 Feb 7;96(1):43-8 [10686550.001]
  • [Cites] Neurogenetics. 2000 Mar;2(4):219-26 [10983717.001]
  • [Cites] Am J Med Genet. 2000 Dec 4;96(6):765-70 [11121177.001]
  • [Cites] Eur Child Adolesc Psychiatry. 2000 Dec;9(4):307-11 [11202107.001]
  • [Cites] Ann Neurol. 2001 May;49(5):618-26 [11357952.001]
  • [Cites] Am J Hum Genet. 2001 Jul;69(1):124-37 [11404818.001]
  • [Cites] Am J Hum Genet. 2001 Jul;69(1):138-47 [11404819.001]
  • [Cites] J Autism Dev Disord. 2001 Apr;31(2):247-8 [11450824.001]
  • [Cites] Am J Hum Genet. 2001 Aug;69(2):327-40 [11452361.001]
  • [Cites] Am J Hum Genet. 2001 Sep;69(3):570-81 [11481586.001]
  • [Cites] Arch Gen Psychiatry. 2001 Nov;58(11):1015-24 [11695947.001]
  • [Cites] Nat Rev Genet. 2001 Dec;2(12):943-55 [11733747.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):97-101 [11731797.001]
  • [Cites] Am J Med Genet. 2001 Dec 8;105(8):609-15 [11811142.001]
  • [Cites] J Autism Dev Disord. 2001 Dec;31(6):537-43 [11814263.001]
  • [Cites] Am J Med Genet. 2002 Jan 8;114(1):99-105 [11840513.001]
  • [Cites] Clin Genet. 2001 Dec;60(6):421-30 [11846734.001]
  • [Cites] Eur J Hum Genet. 2002 Jan;10(1):26-35 [11896453.001]
  • [Cites] Physiol Rev. 2002 Apr;82(2):503-68 [11917096.001]
  • [Cites] Mol Psychiatry. 2002;7(3):311-6 [11920158.001]
  • [Cites] J Neurogenet. 2001;15(3-4):245-59 [12092907.001]
  • [Cites] Ann Med. 2002;34(2):88-95 [12108579.001]
  • [Cites] Med Sci Monit. 2002 Aug;8(8):PR1-6 [12165753.001]
  • [Cites] Am J Hum Genet. 2002 Oct;71(4):777-90 [12192642.001]
  • [Cites] JAMA. 2003 Jan 1;289(1):49-55 [12503976.001]
  • [Cites] Bioinformatics. 2003 Feb 12;19(3):376-82 [12584123.001]
  • [Cites] Am J Hum Genet. 2003 Mar;72(3):539-48 [12567325.001]
  • [Cites] J Autism Dev Disord. 2003 Feb;33(1):93-7 [12708584.001]
  • [Cites] J Autism Dev Disord. 2003 Aug;33(4):365-82 [12959416.001]
  • [Cites] Am J Hum Genet. 2003 Oct;73(4):886-97 [13680528.001]
  • [Cites] Genet Epidemiol. 2003 Nov;25(3):203-13 [14557988.001]
  • [Cites] Am J Hum Genet. 2003 Nov;73(5):1016-26 [14551902.001]
  • [Cites] Hum Hered. 2003;56(1-3):73-82 [14614241.001]
  • [Cites] Genet Epidemiol. 2004 Jan;26(1):61-9 [14691957.001]
  • [Cites] Pediatrics. 2004 May;113(5):e472-86 [15121991.001]
  • [Cites] BMC Bioinformatics. 2004 Apr 30;5:49 [15119966.001]
  • [Cites] J Biol Chem. 2004 Sep 24;279(39):40451-61 [15265862.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2004;5:379-405 [15485354.001]
  • [Cites] J Child Psychol Psychiatry. 1989 May;30(3):405-16 [2745591.001]
  • [Cites] Dev Med Child Neurol. 1994 Aug;36(8):736-42 [8050626.001]
  • [Cites] J Child Psychol Psychiatry. 1994 Jul;35(5):877-900 [7962246.001]
  • [Cites] Psychol Med. 1995 Jan;25(1):63-77 [7792363.001]
  • [Cites] Genetica. 1995;96(1-2):169-78 [7607454.001]
  • [Cites] J Autism Dev Disord. 1997 Oct;27(5):501-17 [9403369.001]
  • (PMID = 16080114.001).
  • [ISSN] 0002-9297
  • [Journal-full-title] American journal of human genetics
  • [ISO-abbreviation] Am. J. Hum. Genet.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P01 NS026630; United States / NINDS NIH HHS / NS / R01 NS042165; United States / NINDS NIH HHS / NS / NS26630; United States / NIA NIH HHS / AG / R01 AG20135; United States / NINDS NIH HHS / NS / R01 NS036768; United States / NIA NIH HHS / AG / R01 AG020135; United States / NINDS NIH HHS / NS / R01 NS42165; United States / NINDS NIH HHS / NS / R01 NS36768
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / Receptors, GABA-A
  • [Other-IDs] NLM/ PMC1226204
  •  go-up   go-down


99. Poulose BK, Griffin MR, Zhu Y, Smalley W, Richards WO, Wright JK, Melvin W, Holzman MD: National analysis of adverse patient safety for events in bariatric surgery. Am Surg; 2005 May;71(5):406-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cumulative incidence at discharge was calculated for accidental puncture or laceration (APL), pulmonary embolus or deep venous thrombosis (PE/DVT), and postoperative respiratory failure (RF).
  • During BaS hospitalization, the cumulative incidences per 1000 discharges of APL, PE/DVT, and RF were 12.6, 3.4, and 7.3, respectively.
  • Risk factors for APL included male gender (odds ratio [OR] 1.6, 95% confidence interval 1.1-2.3, P < 0.05) and age of 40-49 years (OR 1.6 [1.1-2.3], P < 0.05) compared to ages 18-39 years.
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Incidence. Male. Middle Aged. Risk Factors. United States / epidemiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Safety.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15986971.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Grant] United States / AHRQ HHS / HS / T32 HS 13833-01
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


100. Ames PR, Iannaccone L, Alves JD, Margarita A, Lopez LR, Brancaccio V: Factor XIII in primary antiphospholipid syndrome. J Rheumatol; 2005 Jun;32(6):1058-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A cross-sectional study including patients with primary APS (n =29), persistent carriers of idiopathic antiphospholipid antibodies (aPL) with no history of thrombosis (n = 14), thrombotic patients with inherited thrombophilia (n =24), healthy controls (n =28), and patients with mitral and aortic valve prosthesis (n =32, as controls for FXIII only).
  • These associations were weaker in the aPL group (FXIIIa with IgG aCL, p= 0.02, with IgG anti-beta2-GPI, p=0.04).
  • This pathway is not exclusive to primary APS, being present also in thrombotic controls, but the presence of IgG aPL may favor a higher degree of FXIIIa activation in the primary APS group.
  • [MeSH-minor] Adult. Antibodies, Anticardiolipin / metabolism. Arteriosclerosis / metabolism. Arteriosclerosis / pathology. Arteriosclerosis / ultrasonography. Aryldialkylphosphatase / blood. Carotid Arteries / pathology. Carotid Arteries / ultrasonography. Cross-Sectional Studies. Female. Humans. Male. Thrombophilia / genetics. Thrombophilia / metabolism. Thrombophilia / pathology

  • Genetic Alliance. consumer health - Antiphospholipid Syndrome.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15940768.001).
  • [ISSN] 0315-162X
  • [Journal-full-title] The Journal of rheumatology
  • [ISO-abbreviation] J. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antibodies, Anticardiolipin; EC 2.3.2.13 / Factor XIIIa; EC 3.1.8.1 / Aryldialkylphosphatase
  •  go-up   go-down






Advertisement